**CURRICULUM** **VITAE**

George H. McCracken, Jr., M.D.

PERSONAL:

Full Name: George Herbert McCracken, Jr.

Citizenship: United States

Married: Leslie Ann Sanford

Dependents: Two daughters - Kelly and Megan

EDUCATION:

College: Williams College, A.B. 1958

Cornell University Medical College, M.D. 1962

CLINICAL TRAINING:

Internship: Department of Medicine, New York Hospital, 1962-63

New York, New York

Residency: Department of Pediatrics, New York Hospital, 1963-65

New York, New York

Chief Residency: Department of Pediatrics, Southwestern Medical 1965-66

School and Children's Medical Center, Dallas, TX

ACADEMIC APPOINTMENTS:

Instructor in Pediatrics, The University of Texas Southwestern 1965-66

 Medical School at Dallas, Texas

Clinical Assistant Professor of Pediatrics, Howard University 1966-67

 College of Medicine, Washington, DC

Clinical Assistant Professor of Pediatrics, Georgetown University 1967-68

 Medical School, Washington, DC

Assistant Professor of Pediatrics, University of Texas Southwestern 1968

 Medical School at Dallas and Attending Physician, Children's

 Medical Center and Parkland Memorial Hospital, Dallas, TX

Associate Professor of Pediatrics, University of Texas Southwestern 1972

 Medical School at Dallas, Texas

Professor of Pediatrics, University of Texas Southwestern Medical 1976

 School at Dallas, Texas

The George L. MacGregor Professorship in Pediatrics 1991-93

The Sarah M. and Charles E. Seay Chair in Pediatric Infectious 1993-2010

 Diseases

GlaxoSmithKline Distinguished Professor of Pediatric Infectious 2001-2010

 Diseases

George McCracken Distinguished Professor of Pediatric Infectious 2011-

 Diseases

POSITIONS:

President and Treasurer, The National Pediatric Infectious Diseases 1994-2010

 Foundation

MILITARY SERVICE:

Commissioned Officer, U.S.P.H.S. 1966-68

Staff Associate, National Institute of Child Health and Human

 Development, assigned to Infectious Disease Unit, Perinatal

 Research Branch, NINDB

BOARD CERTIFICATION

American Board of Pediatrics 1967

American Board of Pediatrics: Pediatric Infectious Diseases 1994

American Board of Pediatrics: Recertification 2000

TRAINING (FELLOWSHIPS)

Since 1968 Dr McCracken has trained 100 fellows in pediatric infectious disease at UTSWMC at Dallas.

 Additionally, from 1992-2008 he raised more than $4,560,000 for the Pediatric Infectious

 Diseases Society (PIDS) to sponsor 58 two-year PIDS Fellowship Training Awards in the US

ACADEMIC HONORS:

Phi Beta Kappa 1958

Alpha Omega Alpha 1961

Rudolph Matas Lecturer, Tulane University School of Medicine 1979

First Wayne Klein Memorial Lecturer, State University of New York 1980

 at Stony Brook

Emilio Soto Memorial Lecturer, Fairfax Hospital, Northern Virginia 1982

 Pediatric Society

Dr. David Hsia Memorial Lecturer, Loyola University Stritch School 1985

 of Medicine

McLemore Birdsong Lecturer, University of Virginia Health Science 1990

 Center, Charlottesville, VA, April 27, 1990

Distinguished Faculty, Opening Ceremony of Lucille Packard 1991

 Children's Hospital of Stanford University

Phyllis Lewander Memorial Lecturer 1991

 Children's National Medical Center

Lowell A. Glasgow Visiting Professor 1992

 University of Utah Medical Center, Salt Lake City

Sir Leonard Parsons Lecturer 1992

 University of Birmingham Medical School, Birmingham, United Kingdom

Sir Macfarlane Burnet Orator, Australian Society for Infectious 1992

 Diseases, Adelaide, Australia

The Bill Marshall Honorary Lecture, European Society for Pediatric 1993

 Infectious Diseases, Helsinki, Finland

 Keynote speaker. 50th Anniversary of the Hospital Infantil de Mexico

 November, 1993 1993

Delivered the Merle J. Carson Memorial Lecture to Chapter 2 American 1994

 Academy of Pediatrics Spring Meeting, Palm Springs, CA

Elected to Board of Directors, The National Foundation for Infectious 1994

 Diseases

Delivered the First Marjorie Kantor Memorial Lecture. Mercy Children's 1995

 Hospital, Kansas City, MO

E. Cannon Ely Memorial Lecture. Children's Hospital, Boston MA. 1996

Delivered the Bernice C. and Henry P. Goldberg Memorial Lecture. 1996

 Cornell University Medical Center, NY.

David Seegal Alpha Omega Alpha Visiting Professor. Columbia 1998

 University Health Sciences Division, NY.

Russell J. Blattner Lecturer. Baylor College of Medicine, TX 1998

The Frank E. Stevenson MD Professorship. Children’s Hospital Medical 1999

 Center, Cincinnati, OH. March 1999

The Lewis W. Wannamaker Memorial Lecturer. University of Minnesota 1999

 June 1999

The Hugh Carithers Visiting Professorship, University of Florida Health 2000

 Science Center, Jacksonville, FL, April 2000.

The First Stephen Chartrand Memorial Lecture, Creighton University, 2001

 Omaha, NE, September 2001

Dean’s Scholars Program Lectureship. College of Natural Sciences, 2001

 University of Texas, Austin, Texas

The James C. Parke Lecture, Carolinas Medical Center, Charlotte, NC 2003

Best Doctors in America, Voted to the list consistently since 1984 1984-2011

 Donald H. Altman, MD Distinguished Lectureship, Miami Children’s Hospital 2007

 The Congress Honorary Lecture, World Society for Pediatric Infectious 2007

 Diseases, Bangkok, Thailand

 The Richard H Rapkin Memorial Lecture, New Jersey Medical School, Newark, NJ 2008

 The William Leslie Bradford Lecture, Mercy Children’s Hospital, Kansas City, MO 2009

 Presidential Address, I Conferencia de Actualizacion en Pediatria ALAPE, Panama 2011

AWARDS:

Outstanding Teacher Award, John Peter Smith Hospital, Fort Worth, TX 1978-79

Weinstein-Goldenson Award for Scientific Research, United Cerebral 1988

 Palsy Association

Bristol Award for Distinguished Achievements in Infectious 1990

 Diseases, Infectious Diseases Society of America

Faculty Teaching Award, St. Paul Family Medicine Program, 1990

 St. Paul Medical Center, Dallas, TX

Distinguished Service Award, Children's Medical Center 1990

 Foundation, Dallas, TX

Hoechst-Roussel Award for Outstanding Accomplishments 1991

 in Antimicrobial Chemotherapy, American Society for Microbiology

Distinguished Service Award. The Pediatric Infectious Diseases Society. 1997

Outstanding Teacher Award, Children's Medical Center, Dallas, TX 1998

 Voted by Pediatric Residents

 President's Proclamation. American Society for Microbiology. 1998

 Establishment of the annual George McCracken Infectious Disease

 Fellows Awards in recognition of his contributions to the

 Interscience Conference on Antimicrobial Agents and Chemotherapy

 and to the American Society for Microbiology.

Distinguished Physician Award for lifetime achievements in research 2001

 and training in pediatric infectious diseases. The Pediatric Infectious

 Diseases Society

 The Bicentennial Medal from Williams College for Distinguished Achievements 2003

 in pediatric medicine

 Mentor Award for a Distinguished Lifetime Record of Mentorship in Infectious 2003

 Diseases, Infectious Disease Society of America

Ambassador David M. Walters International Pediatric Hall of Fame, Miami 2003

 Children’s Hospital Foundation. Induction for outstanding contributions in the

 area of pediatric Infectious diseases and antimicrobial therapy

 The Maxwell Finland Award for scientific achievements from the National 2004

 Foundation For Infectious Diseases

 Lifetime Contribution to Education in Infectious Disease Award from the 2004

 Section on Infectious Disease of the American Academy of Pediatrics.

 Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and 2005

 Therapeutics from the Pediatric Pharmacy Advocacy Group.

 The Cornell University Medical College Alumnus Award of Distinction 2006

 The Scarsdale High School Distinguished Alumnus Award 2006

 The Kellogg Award for Distinguished Lifetime Achievements in Pediatric 2008

 Medicine, Williams College, Williamstown, MA

 Honorary Doctorate of Medicine, University of Athens, Athens, Greece, 2008

 Special Recognition Certificate for Education, American Academy of Pediatrics 2011

MEMBERSHIPS/EDITORIAL BOARDS:

Co-Founder and Chief Editor, The Pediatric Infectious Disease Journal 1982- Co-Director, The National Pediatric Infectious Disease Seminar 1981-2007

Chairman/Director, Research Rounds: An Educational Course for 1995-2008

 Infectious Disease Fellows in North America

American Society for Microbiology 1970

Society for Pediatric Research 1971

Infectious Diseases Society of America 1972

American Pediatric Society 1975

Editorial Board - Journal of Pediatrics 1975

Fellow, American Academy of Pediatrics 1977

Nominating Committee, Infectious Disease Society of America 1979

Editorial Board, Developmental Pharmacology and Therapeutics 1979

Committee for The Interscience Conference on Antimicrobial 1980-88

 Agents and Chemotherapy (ICAAC)

 Vice-Chairman, Committee for ICAAC 1983-84

 Chairman, Committee for ICAAC 1984-88

 Editorial Board, Antimicrobial Agents and Chemotherapy 1982-

 Committee on Infectious Diseases, American Academy of Pediatrics 1984-90

Council, Pediatric Infectious Disease Society 1987

Associate Editor, Report of The Committee on Infectious 1991

 Diseases (The Red Book), 1991

Chairman, Finance Committee, Pediatric Infectious Diseases Society 1991-

Chairman, Fellowship Awards Committee, Pediatric Infectious Diseases 1992

 Society

Honorary Life Member, Australian Society for Infectious Diseases 1992

GRANTS:

Infectious Disease Training Award, NICHD, National Institutes of Health 1987-1992

Principal Investigator, Pediatric Pharmacology Research Unit Network, NICHD, 2004-2010

 National Institutes of Health

1. McCracken, G.H., Jr. and H.R. Shinefield, *Immunoglobulin concentrations in newborn infants with congenital cytomegalic inclusion disease.* Pediatrics, 1965. **36**(6): p. 933-7.

2. McCracken, G.H. and H.F. Eichenwald, *Antimicrobial therapy in infancy and childhood: 1966.* Pediatr Clin North Am, 1966. **13**(2): p. 231-50.

3. McCracken, G.H. and H.R. Shinefield, *Changes in the pattern of neonatal septicemia and meningitis.* Am J Dis Child, 1966. **112**(1): p. 33-9.

4. Gersony, W.M. and G.H. McCracken, *Purulent pericarditis in infancy.* Pediatrics, 1967. **40**(2): p. 224-32.

5. McCracken, G., *Comparison of provincial hospital plans.* Can Hosp, 1967. **44**(9): p. 54-8.

6. Turino, G.M., R.V. Lourenco, and G.H. McCracken, *Role of connective tissues in large pulmonary airways.* J Appl Physiol, 1968. **25**(6): p. 645-53.

7. Hardy, J.B., et al., *Adverse fetal outcome following maternal rubella after the first trimester of pregnancy.* Jama, 1969. **207**(13): p. 2414-20.

8. Hardy, J.B., et al., *Serum immunoglobulin levels in newborn infants. 3. Some preliminary observations from a survey of cord blood levels in 2,600 infants.* J Pediatr, 1969. **75**(6): p. 1211-23.

9. McCracken, G.H., et al., *Serum immunoglobulin levels in newborn infants. I. Evaluation of a radial diffusion plate methods.* J Pediatr, 1969. **74**(3): p. 378-82.

10. McCracken, G.H. and J.D. Dickerman, *Septicemia and disseminated intravascular coagulation. Occurrence in four asplenic children.* Am J Dis Child, 1969. **118**(3): p. 431-4.

11. McCracken, G.H., H.F. Eichenwald, and J.D. Nelson, *Antimicrobial therapy in theory and practice. II. Clinical approach to antimicrobial therapy.* J Pediatr, 1969. **75**(6): p. 923-36.

12. McCracken, G.H., H.F. Eichenwald, and J.D. Nelson, *Antimicrobial therapy in theoy and practice. I. Clinical pharmacology.* J Pediatr, 1969. **75**(5): p. 742-57.

13. McCracken, G.H., et al., *Serum immunoglobulin levels in newborn infants. II. Survey of cord and follow-up sera from 123 infants with congenital rubella.* J Pediatr, 1969. **74**(3): p. 383-92.

14. McCracken, G.H., et al., *Evaluation of a radial diffusion plate method for determining serum immunoglobulin levels in normal and congenitally infected infants.* J Pediatr, 1969. **75**(6): p. 1204-10.

15. McCracken, G.H., et al., *Congenital cytomegalic inclusion disease. A longitudinal study of 20 patients.* Am J Dis Child, 1969. **117**(5): p. 522-39.

16. Sever, J.L., et al., *Latex reagent for determining IgM levels in cord and newborn sera.* J Immunol, 1969. **102**(3): p. 679-81.

17. Sever, J.L., et al., *Latex reagent for determining IgM levels in cord and newborn sera.* J Immunol, 1969. **102**(3): p. 679-81.

18. Eichenwald, H.F. and G.H. McCracken, *Acute diarrheal disease.* Med Clin North Am, 1970. **54**(2): p. 443-54.

19. McCracken, G.H., H.F. Eichenwald, and J.D. Nelson, *Treatment of Hemophilus influenzae otitis media.* J Pediatr, 1970. **76**(5): p. 802.

20. McCracken, G.H., H.G. Eichenwald, and J.D. Nelson, *Antimicrobial therapy and practice.* J Pediatr, 1970. **76**(5): p. 805.

21. McCracken, G.H., H.F. Einchenwald, and J.D. Nelson, *Tetracyclines.* J Pediatr, 1970. **76**(5): p. 803-4.

22. McCracken, G.H. and L.G. Jones, *Gentamicin in the neonatal period.* Am J Dis Child, 1970. **120**(6): p. 524-33.

23. McCracken, G.H. and R.C. Reynolds, *Primary lymphopenic immunologic deficiency. Disseminated Mycobacterium kansasii infection.* Am J Dis Child, 1970. **120**(2): p. 143-7.

24. McCracken, G.H., *Changing pattern of the antimicrobial susceptibilities of Escherichia coli in neonatal infections.* J Pediatr, 1971. **78**(6): p. 942-7.

25. McCracken, G.H., D.F. Chrane, and M.L. Thomas, *Pharmacologic evaluation of gentamicin in newborn infants.* J Infect Dis, 1971. **124**: p. Suppl 124:214-.

26. McCracken, G.H., D.L. Dowell, and F.N. Marshall, *Double-blind trial of equine antitoxin and human immune globulin in tetanus neonatorum.* Lancet, 1971. **1**(7710): p. 1146-9.

27. McCracken, G.H. and H.F. Eichenwald, *Leukocyte function and the development of opsonic and complement activity in the neonate.* Am J Dis Child, 1971. **121**(2): p. 120-6.

28. McCracken, G.H., N.R. West, and L.J. Horton, *Urinary excretion of gentamicin in the neonatal period.* J Infect Dis, 1971. **123**(3): p. 257-62.

29. Howard, J.B., G.H. McCracken, and J.P. Luby, *Influenza A 2 virus as a cause of croup requiring tracheotomy.* J Pediatr, 1972. **81**(6): p. 1148-50.

30. McCracken, G.H., *Clinical pharmacology of gentamicin in infants 2 to 24 months of age.* Am J Dis Child, 1972. **124**(6): p. 884-7.

31. McCracken, G.H., *The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis.* Am J Dis Child, 1972. **123**(6): p. 547-53.

32. McCracken, G.H. and J.P. Luby, *Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease.* J Pediatr, 1972. **80**(3): p. 488-93.

33. McCracken, G.H., A.G. Weinberg, and M.E. Carlin, *Granulomatous lung disease with progressive deterioration of phagocytic function.* J Pediatr, 1972. **81**(2): p. 267-74.

34. Nelson, J.D. and G.H. McCracken, *The current status of gentamicin for tne neonate and young infant.* Am J Dis Child, 1972. **124**(1): p. 13-4.

35. Kaplan, J.M., G.H. McCracken, and J.D. Nelson, *Infections in children caused by the HB group of bacteria.* J Pediatr, 1973. **82**(3): p. 398-403.

36. Kaplan, J.M., G.H. McCracken, and E. Snyder, *Influence of methodology upon apparent concentrations of antibiotics in tissue.* Antimicrob Agents Chemother, 1973. **3**(2): p. 143-6.

37. Kaplan, J.M., et al., *Clinical pharmacology of tobramycin in newborns.* Am J Dis Child, 1973. **125**(5): p. 656-60.

38. McCracken, G., *Guest editorial: Ribbons from the flower show (William Douglas Piercey).* Can Hosp, 1973. **50**(2): p. 5 p.

39. McCracken, G.H., *Group B streptococci: the new challenge in neonatal infections.* J Pediatr, 1973. **82**(4): p. 703-6.

40. McCracken, G.H., et al., *Clinical pharmacology of penicillin in newborn infants.* J Pediatr, 1973. **82**(4): p. 692-8.

41. McCracken, G.H., J.D. Nelson, and M.L. Thomas, *Discrepancy between carbenicillin and ampicillin activities against enterococci and Listeria.* Antimicrob Agents Chemother, 1973. **3**(3): p. 343-9.

42. Nelson, J.D. and G.H. McCracken, *Clinical pharmacology of carbenicillin and gentamicin in the neonate and comparative efficacy with ampicillin and gentamicin.* Pediatrics, 1973. **52**(6): p. 801-12.

43. Weinberg, A.G., et al., *Monoclonal macroglobulinemia and cytomegalic inclusion disease.* Pediatrics, 1973. **51**(3): p. 518-24.

44. Howard, J.B. and G.H. McCracken, *The spectrum of group B streptococcal infections in infancy.* Am J Dis Child, 1974. **128**(6): p. 815-8.

45. Kaplan, J.M., et al., *Pharmacologic studies in neonates given large dosages of ampicillin.* J Pediatr, 1974. **84**(4): p. 571-7.

46. McCracken, G.H., *Pharmacological basis for antimicrobial therapy in newborn infants.* Am J Dis Child, 1974. **128**(3): p. 407-19.

47. McCracken, G.H. and H.F. Eichenwald, *Antimicrobiol therapy: therapeutic recommendations and a review of newer drugs. Part I. Therapy of infectious conditions.* J Pediatr, 1974. **85**(3): p. 297-312.

48. McCracken, G.H. and J.M. Kaplan, *Penicillin treatment for congenital syphilis. A critical reappraisal.* Jama, 1974. **228**(7): p. 855-8.

49. McCracken, G.H., et al., *Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis.* Lancet, 1974. **2**(7875): p. 246-50.

50. Robbins, J.B., et al., *Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis.* N Engl J Med, 1974. **290**(22): p. 1216-20.

51. Howard, J.B. and G.H. McCracken, *Pharmacological evaluation of amikacin in neonates.* Antimicrob Agents Chemother, 1975. **8**(1): p. 86-90.

52. Howard, J.B. and G.H. McCracken, *Reappraisal of kanamycin usage in neonates.* J Pediatr, 1975. **86**(6): p. 949-56.

53. McCracken, G.H., *Pharmacologic basis for antimicrobial therapy in newborn infants.* Clin Perinatol, 1975. **2**(1): p. 139-61.

54. McCracken, G.H., *Commentary on effects of gentamicin on albumin binding of bilirubin.* J Pediatr, 1975. **86**: p. 615.

55. McCracken, G.H., *Antibiotics in the newborn.* Can Med Assoc J, 1975. **113**: p. 564-570.

56. McCracken, G.H., *Commentary: Does intramuscular penicillin at delivery prevent group B beta hemolytic streptococcal disease of the newborn infant?* J Pediatr, 1975. **87**: p. 496-497.

57. Sarff, L.D., et al., *Epidemiology of Escherichia coli K1 in healthy and diseased newborns.* Lancet, 1975. **1**(7916): p. 1099-104.

58. Thorley, J.D., et al., *Passive transfer of antibodies of maternal origin from blood to cerebrospinal fluid in infants.* Lancet, 1975. **1**(7908): p. 651-3.

59. Ginsburg, C.M., G.H. McCracken, and M.C. Culbertson, *Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.* J Pediatr, 1976. **89**(6): p. 1011-3.

60. Howard, J.B., et al., *Amikacin in newborn infants: Comparative pharmacology with amikacin and clinical efficacy in 45 neonates with bacterial disease.* Chemother, 1976. **10**: p. 205.

61. McCracken, G.H., *Rapid identification of specific etiology in meningitis.* J Pediatr, 1976. **88**(4 Pt. 1): p. 706-8.

62. McCracken, G.H., *Managing neonatal infections.* Hosp Pract, 1976. **11**(2): p. 49-57.

63. McCracken, G.H., *Neonatal septicemia and meningitis.* Hosp Pract, 1976. **11**(1): p. 89-97.

64. McCracken, G.H. and W.E. Feldman, *Editorial: Neonatal group B streptococcal infection.* J Pediatr, 1976. **89**(2): p. 203-4.

65. McCracken, G.H. and S.G. Mize, *A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.* J Pediatr, 1976. **89**(1): p. 66-72.

66. McCracken, G.H. and J.D. Nelson, *Commentary: An appraisal of tobramycin usage in pediatrics.* J Pediatr, 1976. **88**(2): p. 315-7.

67. McCracken, G.H. and L.D. Sarff, *Endotoxin in cerebrospinal fluid: Detection in neonates with bacterial meningitis.* J Am Med Assoc, 1976. **1976**(235): p. 617.

68. McCracken, G.H. and N. Threlkeld, *Kanamycin dosage in newborn infants.* J Pediatr, 1976. **89**(2): p. 313-4.

69. Sarff, L.D., L.H. Platt, and G.H. McCracken, *Cerebrospinal fluid evaluation in neonates: comparison of high-risk infants with and without meningitis.* J Pediatr, 1976. **88**(3): p. 473-7.

70. Schiffer, M.S., et al., *A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli.* Pediatr Res, 1976. **10**(2): p. 82-7.

71. Ginsburg, C.M., et al., *Haemophilus influenzae type b disease. Incidence in a day-care center.* Jama, 1977. **238**(7): p. 604-7.

72. Glode, M.P., et al., *Neonatal meningitis due of Escherichia coli K1.* J Infect Dis, 1977. **136 Suppl**: p. S93-7.

73. Hieber, J.P., A.J. Nelson, and G.H. McCracken, *Acute disseminated staphylococcal disease in childhood.* Am J Dis Child, 1977. **131**(2): p. 181-5.

74. McCracken, G.F. and J.W. Bradbury, *Paternity and Genetic Heterogeneity in the Polygynous Bat, Phyllostomus hastatus.* Science, 1977. **198**(4314): p. 303-6.

75. McCracken, G.H., *Intraventricular treatment of neonatal meningitis due to gram-negative bacilli.* J Pediatr, 1977. **91**(6): p. 1037-8.

76. McCracken, G.H., *Dosage of ampicillin in the treatment of bacterial meningitis.* J Pediatr, 1977. **90**(4): p. 670-1.

77. MCCracken, G.H., *Reply to "Opening Pandora's Box".* J Pediatr, 1977. **91**: p. 165-166.

78. McCracken, G.H. and P.S. Lietman, *Commentary: assessment of amikacin for pediatric usage.* J Pediatr, 1977. **91**(2): p. 358-60.

79. McCracken, G.H., N. Threlkeld, and M.L. Thomas, *Intravenous administration of kanamycin and gentamicin in newborn infants.* Pediatrics, 1977. **60**(4): p. 463-6.

80. Sarff, L.D. and G.H. McCracken, *Methicillin-associated nephropathy or cystitis.* J Pediatr, 1977. **90**(6): p. 1031-2.

81. Sarff, L.D., et al., *Clinical pharmacology of methicillin in neonates.* J Pediatr, 1977. **90**(6): p. 1005-8.

82. Wientzen, R.L. and G.H. McCracken, *Pathogenesis and management of neonatal sepsis and meningitis.* Curr Probl Pediatr, 1977. **8**(2): p. 1-61.

83. Eichenwald, H.F. and G.H. McCracken, *Antimicrobial therapy in infants and children. Part I. Review of antimicrobial agents.* J Pediatr, 1978. **93**(3): p. 337-56.

84. Ginsburg, C.M., et al., *Clinical pharmacology of cefadroxil in infants and children.* Antimicrob Agents Chemother, 1978. **13**(5): p. 845-8.

85. Ginsburg, C.M., et al., *Association between cross-reacting Escherichia coli K100 and disease caused by Haemophilus influenzae type b.* Infect Immun, 1978. **22**(2): p. 339-42.

86. McCracken, G.H., *Lung abscess in childhood.* Hosp Pract, 1978. **13**(8): p. 35-6.

87. McCracken, G.H., *Commentary: Aerobic and anaerobic bacteriology of acute otitis media in children.* J Pediatr, 1978. **92**: p. 15.

88. McCracken, G.H. and H.F. Eichenwald, *Antimicrobial therapy in infants and children. Part II. Therapy of infectious conditions.* J Pediatr, 1978. **93**(3): p. 357-77.

89. McCracken, G.H. and D.V. Eitzman, *Necrotizing enterocolitis.* Am J Dis Child, 1978. **132**(12): p. 1167-8.

90. McCracken, G.H., et al., *Pharmacokinetics of cefaclor in infants and children.* J Antimicrob Chemother, 1978. **4**(6): p. 515-21.

91. McCracken, G.H., et al., *Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability.* Pediatrics, 1978. **62**(5): p. 738-43.

92. Siegel, J.D. and G.H. McCracken, *Detection of group B streptococcal antigens in body fluids of neonates.* J Pediatr, 1978. **93**(3): p. 491-2.

93. Siegel, J.D. and G.H. McCracken, *Group D streptococcal infections.* J Pediatr, 1978. **93**(3): p. 542-3.

94. Tetzlaff, T.R., G.H. McCracken, and J.D. Nelson, *Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis.* J Pediatr, 1978. **92**(3): p. 485-90.

95. Tetzlaff, T.R., G.H. McCracken, and M.L. Thomas, *Bioavailability of cephalexin in children: relationship to drug formulations and meals.* J Pediatr, 1978. **92**(2): p. 292-4.

96. Eichenwald, H.F. and G.H. McCracken, *Use of trimethoprim-sulfamethoxazole in otitis media. Reply.* J Pediatr, 1979. **95**(2): p. 326-8.

97. Finitzo-Hieber, T., et al., *Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up study.* Pediatrics, 1979. **63**(3): p. 443-50.

98. Ginsburg, C.M. and G.H. McCracken, *Pharmacokinetics of cephradine suspension infants and children.* Antimicrob Agents Chemother, 1979. **16**(1): p. 74-6.

99. Ginsburg, C.M., et al., *Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children.* Pediatrics, 1979. **64**(5): p. 627-31.

100. McCracken, G.H., *Septic arthritis in a neonate.* Hosp Pract, 1979. **14**(3): p. 158, 161, 164.

101. McCracken, G.H., *Treatment of ampicillin-resistant Haemophilus influenzae in soft tissue infections with high doses of ampicillin (Editorial).* J Pediatr, 1979. **94**: p. 987.

102. Schaad, U.B., et al., *Management of atypical mycobacterial lymphadenitis in childhood: a review based on 380 cases.* J Pediatr, 1979. **95**(3): p. 356-60.

103. Siegel, J.D. and G.H. McCracken, *Neonatal lung abscess. A report of six cases.* Am J Dis Child, 1979. **133**(9): p. 947-9.

104. Siegel, J.D., et al., *Pharmacokinetic properties of netilmicin in newborn infants.* Antimicrob Agents Chemother, 1979. **15**(2): p. 246-53.

105. Sirinavin, S. and G.H. McCracken, *Primary suppurative myositis in children.* Am J Dis Child, 1979. **133**(3): p. 263-5.

106. Sirinavin, S., J.D. Nelson, and G.H. McCracken, *Pitfalls in collecting blood specimens for antibiotic assay.* Antimicrob Agents Chemother, 1979. **15**(3): p. 481-3.

107. Wientzen, R.L., et al., *Localization and therapy of urinary tract infections of childhood.* Pediatrics, 1979. **63**(3): p. 467-74.

108. Ginsburg, C.M. and G.H. McCracken, *Cefaclor and cefadroxil: a commentary on their properties and possible indications for use in pediatrics.* J Pediatr, 1980. **96**(2): p. 340-2.

109. Ginsburg, C.M. and G.H. McCracken, *Bioavailability of cefadroxil capsules and suspension in pediatric patients.* J Int Med Res, 1980. **8**(Suppl 1): p. 9-14.

110. Ginsburg, C.M., et al., *A controlled comparative study of penicillin V and cefadroxil therapy of group A streptococcal tonsillopharyngitis.* J Int Med Res, 1980. **8**(Suppl 1): p. 82-6.

111. Horner, D.B., et al., *A comparison of three antibiotic regimens for eradication of Haemophilus influenzae type b from the pharynx of infants and children.* Pediatrics, 1980. **66**(1): p. 136-8.

112. McCracken, G.H., *The cephalosporins: a perspective on their properties and indications for use in pediatrics.* J Int Med Res, 1980. **8**(Suppl 1): p. 45-9.

113. McCracken, G.H., et al., *Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease.* Pediatrics, 1980. **66**(1): p. 17-21.

114. McCracken, G.H., S.G. Mize, and N. Threlkeld, *Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group.* Lancet, 1980. **1**(8172): p. 787-91.

115. Schaad, U.B., et al., *Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.* Antimicrob Agents Chemother, 1980. **17**(3): p. 406-11.

116. Schaad, U.B., G.H. McCracken, and J.D. Nelson, *Pyogenic arthritis of the sacroiliac joint in pediatric patients.* Pediatrics, 1980. **66**(3): p. 375-9.

117. Schaad, U.B., G.H. McCracken, and J.D. Nelson, *Clinical pharmacology and efficacy of vancomycin in pediatric patients.* J Pediatr, 1980. **96**(1): p. 119-26.

118. Shelton, S., J.D. Nelson, and G.H. McCracken, *In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.* Antimicrob Agents Chemother, 1980. **18**(3): p. 476-9.

119. Siegel, J.D., et al., *Single-dose penicillin prophylaxis against neonatal group B streptococcal infections. A controlled trial in 18,738 newborn infants.* N Engl J Med, 1980. **303**(14): p. 769-75.

120. Sirinavin, S., G.H. McCracken, and J.D. Nelson, *Determining gentamicin dosage in infants and children with renal failure.* J Pediatr, 1980. **96**(2): p. 331-4.

121. Wientzen, R., et al., *Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy.* Am J Dis Child, 1980. **134**(12): p. 1134-8.

122. Cox, F., et al., *Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease.* Jama, 1981. **245**(10): p. 1043-5.

123. Ginsburg, C.M., et al., *Comparative pharmacokinetics of bacampicillin and ampicillin suspensions in infants and children.* Rev Infect Dis, 1981. **3**(1): p. 117-20.

124. Ginsburg, C.M., G.H. McCracken, and J.D. Nelson, *Pharmacology of oral antibiotics used for treatment of otitis media and tonsillopharyngitis in infants and children.* Ann Otol Rhinol Laryngol Suppl, 1981. **90**(3 Pt 3): p. 37-43.

125. Ginsburg, C.M., et al., *Comparative pharmacokinetics of cyclacillin and amoxicillin in infants and children.* Antimicrob Agents Chemother, 1981. **19**(6): p. 1086-8.

126. McCracken, G.H., *use of antibiotics in neonates and low birthweight infants.* Japanese J of Pediatrics, 1981. **34**: p. 2241-2250.

127. McCracken, G.H., et al., *Evaluation of short-term antibiotic therapy in children with uncomplicated urinary tract infections.* Pediatrics, 1981. **67**(6): p. 796-801.

128. Murphy, T.V., et al., *Emergence of rifampin-resistant Haemophilus influenzae after prophylaxis.* J Pediatr, 1981. **99**(3): p. 406-9.

129. Patamasucon, P., J.D. Siegel, and G.H. McCracken, *Streptococcal submandibular cellulitis in young infants.* Pediatrics, 1981. **67**(3): p. 378-80.

130. Schaad, U., *Primary meningococcal arthritis.* Infection, 1981. **9**: p. 170-173.

131. Schaad, U.B. and G.H. McCracken, *Pharmacologic basis for antimicrobial therapy of neonatal meningitis.* Helv Paediatr Acta, 1981. **36**(1): p. 19-30.

132. Schaad, U.B., et al., *Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.* J Infect Dis, 1981. **143**(2): p. 156-63.

133. Schaad, U.B., et al., *Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.* J Pediatr, 1981. **98**(1): p. 129-36.

134. Schaad, U.B., J.D. Nelson, and G.H. McCracken, *Pharmacology and efficacy of vancomycin for staphylococcal infections in children.* Rev Infect Dis, 1981. **3 suppl**: p. S282-8.

135. Schaad, U.B., J.D. Nelson, and G.H. McCracken, *Recrudescence and relapse in bacterial meningitis of childhood.* Pediatrics, 1981. **67**(2): p. 188-95.

136. Siegel, J.D. and G.H. McCracken, *Sepsis neonatorum.* N Engl J Med, 1981. **304**(11): p. 642-7.

137. M., D.R., et al., *Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis.* Antimicrob Agents Chemother, 1982. **22**(6): p. 990-4.

138. Chartrand, S.A. and G.H. McCracken, *Staphylococcal pneumonia in infants and children.* Pediatr Infect Dis, 1982. **1**(1): p. 19-23.

139. Del Rio, M., et al., *Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.* Antimicrob Agents Chemother, 1982. **22**(4): p. 622-7.

140. del Rio Mde, L., et al., *Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis.* Antimicrob Agents Chemother, 1982. **22**(6): p. 990-4.

141. Feldman, W.E., et al., *Relation of concentrations of Haemophilus influenzae type b in cerebrospinal fluid to late sequelae of patients with meningitis.* J Pediatr, 1982. **100**(2): p. 209-12.

142. Ginsburg, C.M. and G.H. McCracken, *Comparison of salivary concentrations of rifampin and cefaclor: a rationale for chemoprophylaxis of Hemophilus influenzae type b disease.* Clin Pediatr (Phila), 1982. **21**(7): p. 397-9.

143. Ginsburg, C.M. and G.H. McCracken, *Urinary tract infections in young infants.* Pediatrics, 1982. **69**(4): p. 409-12.

144. Ginsburg, C.M., G.H. McCracken, and M. Petruska, *Once-daily cefadroxil versus twice-daily cefaclor for treatment of acute urinary tract infections in children.* J Antimicrob Chemother, 1982. **10 Suppl B**: p. 53-6.

145. Ginsburg, C.M., et al., *Treatment of Group A streptococcal pharyngitis in children. Results of a prospective, randomized study of four antimicrobial agents.* Clin Pediatr (Phila), 1982. **21**(2): p. 83-8.

146. Ginsburg, C.M., et al., *Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate.* Pediatr Infect Dis, 1982. **1**(6): p. 384-7.

147. Ginsburg, C.M., G.H. McCracken, and T.C. Zweighaft, *Serum penicillin concentrations after intramuscular administration of benzathine penicillin G in children.* Pediatrics, 1982. **69**(4): p. 452-4.

148. Gulig, P.A., et al., *Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease.* Infect Immun, 1982. **37**(1): p. 82-8.

149. McCracken, G.H., *Antimicrobial prophylaxis for pediatric infectious diseases.* Pediatr Infect Dis, 1982. **1**: p. S10-S13.

150. McCracken, G.H., *Management of urinary tract infections in children.* Pediatr Infect Dis, 1982. **1**: p. S52-S56.

151. McCracken, G.H. and J.D. Nelson, *The third generation cephalosporins and the pediatric practitioner.* Pediatr Infect Dis, 1982. **1**(2): p. 123-5.

152. McCracken, G.H., J.D. Nelson, and L. Grimm, *Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.* Antimicrob Agents Chemother, 1982. **21**(2): p. 262-7.

153. McCracken, G.H. and U.B. Schaad, *The pharmacologic basis for moxalactam therapy for gram-negative enteric bacillary meningitis of infancy.* Rev Infect Dis, 1982. **4 Suppl**: p. S603-5.

154. McCracken, G.H. and U.B. Schaad, *Pharmacokinetics of moxalactam in neonates and young infants.* Rev Infect Dis, 1982. **4 Suppl**: p. S595-6.

155. McCracken, G.H., N.E. Threlkeld, and M.L. Thomas, *Pharmacokinetics of cefotaxime in newborn infants.* Antimicrob Agents Chemother, 1982. **21**(4): p. 683-4.

156. Nelson, J. and G.H. McCracken, *Interview with Sergio Stagno. Isolation precautions for patients with cytomegalovirus infection.* Pediatr Infect Dis, 1982. **1**: p. 145-147.

157. Nelson, J. and G.H. McCracken, *Interview with Larry H. Taber. Evaluation and management of syphilis in pregnant women and newborn infants.* Pediatr Infect Dis, 1982. **1**: p. 224-227.

158. Nelson, J. and G.H. McCracken, *Interview with Philip A. Brunell. Contagion and Varicella-Zoster virus.* Pediatr Infect Dis, 1982. **1**: p. 304-307.

159. Nelson, J.D. and G.H. McCracken, *Mezlocillin and related antibiotics.* Pediatr Infect Dis, 1982. **1**(1): p. 42-3.

160. Patamasucon, P. and G.H. McCracken, *Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis.* Antimicrob Agents Chemother, 1982. **21**(3): p. 390-2.

161. Schaad, U.B., et al., *Mecillinam alone and in combination with ampicillin or moxalactam in experimental Escherichia coli meningitis.* Infection, 1982. **10**(2): p. 90-6.

162. Siegel, J.D., et al., *Single-dose penicillin prophylaxis of neonatal group-B-streptococcal disease.* Lancet, 1982. **1**(8287): p. 1426-30.

163. Del Rio, M., et al., *Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children.* Lancet, 1983. **1**(8336): p. 1241-4.

164. del Rio, M.A., et al., *Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children.* Lancet, 1983. **1**(8336): p. 1241-4.

165. Fulginiti, V.A., J.D. Nelson, and G.H. McCracken, *Panel on immunizations.* Pediatr Infect Dis, 1983. **2**(3 Suppl): p. S64-9.

166. Ginsburg, C.M., G.H. McCracken, and K. Olsen, *Pharmacology of ketoconazole suspension in infants and children.* Antimicrob Agents Chemother, 1983. **23**(5): p. 787-9.

167. Ginsburg, C.M., et al., *Effect of feeding on bioavailability of griseofulvin in children.* J Pediatr, 1983. **102**(2): p. 309-11.

168. McCracken, G.H., *Pharmacokinetic and bacteriological correlations between antimicrobial therapy of experimental meningitis in rabbits and meningitis in humans: a review.* J Antimicrob Chemother, 1983. **12 Suppl D**: p. 97-108.

169. McCracken, G.H., *Comparative evaluation of the aminopenicillins for oral use.* Pediatr Infect Dis, 1983. **2**(4): p. 317-20.

170. McCracken, G.H., *Penicillin allergy.* Pediatr Infect Dis, 1983. **2**(3 Suppl): p. S6-8.

171. McCracken, G.H., *New concepts in the management of infants and children with meningitis.* Pediatr Infect Dis, 1983. **2**(3 Suppl): p. S51-5.

172. McCracken, G.H., *New antimicrobics for the pediatrician.* Pediatr Infect Dis, 1983. **2**(3 Suppl): p. S1-5.

173. McCracken, G.H. and G. Nelson, *Interview with Frank A. Oski. Prevention of pneumococcal infection in children with sickle cell hemoglobinopathy.* Pediatr Infect Dis, 1983. **2**: p. 184-186.

174. McCracken, G.H. and J. Nelson, *Interview with Carol Baker. Prevention of neonatal group B streptococcal disease.* Pediatr Infect Dis, 1983. **2**: p. 1-4.

175. McCracken, G.H., et al., *Ceftriaxone pharmacokinetics in newborn infants.* Antimicrob Agents Chemother, 1983. **23**(2): p. 341-3.

176. McCracken, G.M., *A comparison of the pharmacokinetics of bacampicillin, ampicillin, amoxicillin, and cyclacillin: oral administration in infants and children.* Bull N Y Acad Med, 1983. **59**(5): p. 468-76.

177. Murphy, T.V., et al., *Rifampin prophylaxis v placebo for household contacts of children with Hemophilus influenzae type b disease.* Am J Dis Child, 1983. **137**(7): p. 627-32.

178. Murphy, T.V., et al., *Haemophilus influenzae type b disease after rifampin prophylaxis in a day care center: possible reasons for its failure.* Pediatr Infect Dis, 1983. **2**(3): p. 193-8.

179. Nelson, J.D. and G.H. McCracken, *Interview with Philip A. Pizzo. Isolation techniques in hospitals.* Pediatr Infect Dis, 1983. **2**: p. 94-98.

180. Patamasucon, P. and G.H. McCracken, *An in vitro study of new antibiotic: thienamycin.* J Med Assoc Thai, 1983. **66**(11): p. 708-12.

181. Sakata, Y., A. Boccazzi, and G.H. McCracken, *Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis.* Antimicrob Agents Chemother, 1983. **23**(2): p. 213-7.

182. Bluestone, C.D., et al., *Panel discussion: management of children with recurrent or chronic otitis media with effusion.* Pediatr Infect Dis, 1984. **3**(4): p. 397-400.

183. Freij, B.J., et al., *Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases.* Pediatr Infect Dis, 1984. **3**(6): p. 578-91.

184. Freij, B.J., T.P. Votteler, and G.H. McCracken, *Primary peritonitis in previously healthy children.* Am J Dis Child, 1984. **138**(11): p. 1058-61.

185. Ginsburg, C.M., et al., *Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations.* Am J Dis Child, 1984. **138**(6): p. 536-9.

186. Grossman, M., et al., *Consensus: management of presumed bacterial pneumonia in ambulatory children.* Pediatr Infect Dis, 1984. **3**(6): p. 497-500.

187. Gulig, P.A., et al., *Immunogenic proteins in cell-free culture supernatants of Haemophilus influenzae type b.* Infect Immun, 1984. **44**(1): p. 41-8.

188. Hellerstein, S., et al., *Consensus: roentgenographic evaluation of children with urinary tract infections.* Pediatr Infect Dis, 1984. **3**(4): p. 291-3.

189. Jackson, M.A., et al., *Relatively penicillin-resistant pneumococcal infections in pediatric patients.* Pediatr Infect Dis, 1984. **3**(2): p. 129-32.

190. Lin, T.Y., J.D. Nelson, and G.H. McCracken, *Fever during treatment for bacterial meningitis.* Pediatr Infect Dis, 1984. **3**(4): p. 319-22.

191. McCracken, G.F., *Communal nursing in mexican free-tailed bat maternity colonies.* Science, 1984. **223**(4640): p. 1090-1.

192. McCracken, G.H., *Management of neonatal meningitis, 1984.* J Antimicrob Chemother, 1984. **14 Suppl B**: p. 23-31.

193. McCracken, G.H., *Antimicrobial therapy for acute otitis media.* Pediatr Infect Dis, 1984. **3**(4): p. 383-6.

194. McCracken, G.H., *Management of bacterial meningitis in infants and children. Current status and future prospects.* Am J Med, 1984. **76**(5A): p. 215-23.

195. McCracken, G.H., *Post-exposure rabies prophylaxis.* Pediatr Infect Dis, 1984. **3**(3 Suppl): p. S41-4.

196. McCracken, G.H., *Recurrent urinary tract infections in children.* Pediatr Infect Dis, 1984. **3**(3 Suppl): p. S28-30.

197. McCracken, G.H., *New developments in the management of children with bacterial meningitis.* Pediatr Infect Dis, 1984. **3**(3 Suppl): p. S32-4.

198. McCracken, G.H., et al., *Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation.* Jama, 1984. **252**(11): p. 1427-32.

199. McCracken, G.H., N. Threlkeld, and M.L. Thomas, *Pharmacokinetics of ceftazidime in newborn infants.* Antimicrob Agents Chemother, 1984. **26**(4): p. 583-4.

200. Odio, C., G.H. McCracken, and J.D. Nelson, *CSF shunt infections in pediatrics. A seven-year experience.* Am J Dis Child, 1984. **138**(12): p. 1103-8.

201. Odio, C., G.H. McCracken, and J.D. Nelson, *Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children.* J Pediatr, 1984. **105**(3): p. 491-3.

202. Odio, C., G.H. McCracken, and J.D. Nelson, *Disseminated adenovirus infection: a case report and review of the literature.* Pediatr Infect Dis, 1984. **3**(1): p. 46-9.

203. Odio, C., et al., *Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures.* Am J Dis Child, 1984. **138**(1): p. 17-9.

204. Odio, C., M.L. Thomas, and G.H. McCracken, *Pharmacokinetics and bacteriological efficacy of mezlocillin in experimental Escherichia coli and Listeria monocytogenes meningitis.* Antimicrob Agents Chemother, 1984. **25**(4): p. 427-32.

205. Odio, C., et al., *Pharmacokinetic properties of mezlocillin in newborn infants.* Antimicrob Agents Chemother, 1984. **25**: p. 556-55.

206. Overall, J.C., et al., *Prophylactic or anticipatory antiviral therapy for newborns exposed to herpes simplex infection.* Pediatr Infect Dis, 1984. **3**(3): p. 193-5.

207. Sakata, Y., et al., *Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b.* Antimicrob Agents Chemother, 1984. **25**(1): p. 29-32.

208. Thisyakorn, U., et al., *Detection of teichoic acid antibodies in children with staphylococcal infections.* Pediatr Infect Dis, 1984. **3**(3): p. 222-5.

209. Tim, M.W., et al., *Non-neonatal infection due to Listeria monocytogenes.* Pediatr Infect Dis, 1984. **3**(3): p. 213-7.

210. Bluestone, C.D., et al., *Consensus: management of the child with a chronic draining ear.* Pediatr Infect Dis, 1985. **4**(6): p. 607-12.

211. Breese, B.B., et al., *Consensus: difficult management problems in children with streptococcal pharyngitis.* Pediatr Infect Dis, 1985. **4**(1): p. 10-3.

212. Brunell, P.A., et al., *American Academy of Pediatrics. Committee on Infectious Diseases. Recommendations for using pneumococcal vaccine in children.* Pediatrics, 1985. **75**(6): p. 1153-8.

213. Finitzo-Hieber, T., G.H. McCracken, and K.C. Brown, *Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin.* J Pediatr, 1985. **106**(1): p. 129-36.

214. Freij, B.J., et al., *Pharmacokinetics of imipenem-cilastatin in neonates.* Antimicrob Agents Chemother, 1985. **27**(4): p. 431-5.

215. Ginsburg, C.M., et al., *Seroepidemiology of the group-A streptococcal carriage state in a private pediatric practice.* Am J Dis Child, 1985. **139**(6): p. 614-7.

216. Ginsburg, C.M., et al., *Pharmacokinetics and bactericidal activity of sultamicillin in infants and children.* J Antimicrob Chemother, 1985. **15**(3): p. 345-51.

217. Ginsburg, C.M., et al., *Pharmacokinetics and bactericidal activity of cefuroxime axetil.* Antimicrob Agents Chemother, 1985. **28**(4): p. 504-7.

218. Kimura, A., et al., *A minor high-molecular-weight outer membrane protein of Haemophilus influenzae type b is a protective antigen.* Infect Immun, 1985. **47**(1): p. 253-9.

219. Lin, T.Y., et al., *Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis.* Jama, 1985. **253**(24): p. 3559-63.

220. McCracken, G.H., *Use of third-generation cephalosporins for treatment of neonatal infections.* Am J Dis Child, 1985. **139**(11): p. 1079-80.

221. McCracken, G.H., *Prevention of genitourinary infections.* Pediatr Infect Dis, 1985. **4**(4): p. 429-31.

222. McCracken, G.H., *New antimicrobial agents for pediatricians.* Pediatr Infect Dis, 1985. **4**(3 Suppl): p. S10-2.

223. McCracken, G.H. and Y. Sakata, *Antimicrobial therapy of experimental meningitis caused by Streptococcus pneumoniae strains with different susceptibilities to penicillin.* Antimicrob Agents Chemother, 1985. **27**(2): p. 141-5.

224. McCracken, G.H., Y. Sakata, and K.D. Olsen, *Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.* Antimicrob Agents Chemother, 1985. **27**(4): p. 655-6.

225. Murphy, T.V., et al., *Pharyngeal colonization with Haemophilus influenzae type b in children in a day care center without invasive disease.* J Pediatr, 1985. **106**(5): p. 712-6.

226. Murray, B.E., et al., *Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries.* J Infect Dis, 1985. **152**(6): p. 1107-13.

227. Sato, K., et al., *Bacteriological efficacy of nafcillin and vancomycin alone or combined with rifampicin or amikacin in experimental meningitis due to methicillin-susceptible or -resistant Staphylococcus aureus.* Jpn J Antibiot, 1985. **38**(8): p. 2155-62.

228. Klein, J.O., R.D. Feigin, and G.H. McCracken, *Report of the Task Force on Diagnosis and Management of Meningitis.* Pediatrics, 1986. **78**(5 Pt 2): p. 959-82.

229. Likitnukul, S., et al., *Role of genital mycoplasmas in young infants with suspected sepsis.* J Pediatr, 1986. **109**(6): p. 971-4.

230. Likitnukul, S., G.H. McCracken, and J.D. Nelson, *Arthritis in children with bacterial meningitis.* Am J Dis Child, 1986. **140**(5): p. 424-7.

231. McCracken, G. and S. Bognanni, *Iowa employers use small area analysis in benefits reform.* Business and health, 1986. **3**(9): p. 14-6.

232. McCracken, G.H., *Diagnosis and management of children with streptococcal pharyngitis.* Pediatr Infect Dis, 1986. **5**(6): p. 754-9.

233. McCracken, G.H., *Aminoglycoside toxicity in infants and children.* Am J Med, 1986. **80**(6B): p. 172-8.

234. McCracken, G.H., *Current status of antibiotic treatment for Mycoplasma pneumoniae infections.* Pediatr Infect Dis, 1986. **5**(1): p. 167-71.

235. McCracken, G.H., et al., *Panel discussion: bronchitis and bronchiolitis.* Pediatr Infect Dis, 1986. **5**(6): p. 766-9.

236. Odio, C.M., et al., *Cefotaxime vs. conventional therapy for the treatment of bacterial meningitis of infants and children.* Pediatr Infect Dis, 1986. **5**(4): p. 402-7.

237. Simon, M.W. and G.H. McCracken, *Neonatal cytomegalovirus infection.* J Ky Med Assoc, 1986. **84**(7): p. 345-50.

238. Syrogiannopoulos, G.A., G.H. McCracken, and J.D. Nelson, *Osteoarticular infections in children with sickle cell disease.* Pediatrics, 1986. **78**(6): p. 1090-6.

239. Syrogiannopoulos, G.A., J.D. Nelson, and G.H. McCracken, *Subdural collections of fluid in acute bacterial meningitis: a review of 136 cases.* Pediatr Infect Dis, 1986. **5**(3): p. 343-52.

240. Arvin, A.M., et al., *Consensus: management of the patient with herpes simplex encephalitis.* Pediatr Infect Dis J, 1987. **6**(1): p. 2-5.

241. Gonzales, F.R., et al., *Cloning and expression in Escherichia coli of the gene encoding the heat-modifiable major outer membrane protein of Haemophilus influenzae type b.* Infect Immun, 1987. **55**(12): p. 2993-3000.

242. Gulig, P.A., et al., *Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b.* Infect Immun, 1987. **55**(3): p. 513-20.

243. Israele, V., A. Darabi, and G.H. McCracken, *The role of bacterial virulence factors and Tamm-Horsfall protein in the pathogenesis of Escherichia coli urinary tract infection in infants.* Am J Dis Child, 1987. **141**(11): p. 1230-4.

244. Kimura, A., et al., *Haemophilus influenzae type b lipooligosaccharide: stability of expression and association with virulence.* Infect Immun, 1987. **55**(9): p. 1979-86.

245. Klein, J.O., R.D. Feigin, and G.H. McCracken, *Questions about task force on meningitis--recommendations.* Pediatrics, 1987. **80**(1): p. 121.

246. Likitnukul, S., et al., *Epididymitis in children and adolescents. A 20-year retrospective study.* Am J Dis Child, 1987. **141**(1): p. 41-4.

247. Likitnukul, S., et al., *Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants.* Antimicrob Agents Chemother, 1987. **31**(1): p. 81-3.

248. Likitnukul, S., et al., *Rarity of genital Mycoplasma infection in young infants with aseptic meningitis.* J Pediatr, 1987. **110**(6): p. 998.

249. McCracken, G.H., *Selection of antimicrobial agents for treatment of acute otitis media with effusion.* Pediatr Infect Dis J, 1987. **6**(10): p. 985-8.

250. McCracken, G.H., *New era for orally administered antibiotics: use of sequential parenteral-oral antibiotic therapy for serious infectious diseases of infants and children.* Pediatr Infect Dis J, 1987. **6**(10): p. 951-3.

251. McCracken, G.H., *Novel approaches to therapy of meningitis.* Bull N Y Acad Med, 1987. **63**(6): p. 500-6.

252. McCracken, G.H., *Choosing among the orally administered antibiotics.* Pediatr Infect Dis J, 1987. **6**(6): p. 593-7.

253. McCracken, G.H., *Diagnosis and management of acute urinary tract infections in infants and children.* Pediatr Infect Dis J, 1987. **6**(1): p. 107-12.

254. McCracken, G.H., et al., *Consensus report: antimicrobial therapy for bacterial meningitis in infants and children.* Pediatr Infect Dis J, 1987. **6**(6): p. 501-5.

255. Odio, C.M., et al., *Comparative efficacy of ceftazidime vs. carbenicillin and amikacin for treatment of neonatal septicemia.* Pediatr Infect Dis J, 1987. **6**(4): p. 371-7.

256. Patrick, C.C., et al., *Antigenic characterization of the oligosaccharide portion of the lipooligosaccharide of nontypable Haemophilus influenzae.* Infect Immun, 1987. **55**(12): p. 2902-11.

257. Patrick, C.C., G.H. McCracken, and E.J. Hansen, *Immune response to Haemophilus influenzae type b lipooligosaccharide in infants with Haemophilus meningitis.* J Infect Dis, 1987. **156**(3): p. 516-20.

258. Sande, M.A., W.M. Scheld, and G.H. McCracken, *Summary of a workshop: Pathophysiology of bacterial meningitis - implications for new management strategies.* Pediatr Infect Dis, 1987. **6**: p. 1167-1171.

259. Syrogiannopoulos, G.A., et al., *Pharmacokinetics and bacteriological efficacy of ticarcillin-clavulanic acid (timentin) in experimental Escherichia coli K-1 and Haemophilus influenzae type b meningitis.* Antimicrob Agents Chemother, 1987. **31**(9): p. 1296-300.

260. Syrogiannopoulos, G.A., K.D. Olsen, and G.H. McCracken, *Mannitol treatment in experimental Haemophilus influenzae type b meningitis.* Pediatr Res, 1987. **22**(2): p. 118-22.

261. Syrogiannopoulos, G.A., et al., *Dexamethasone in the treatment of experimental Haemophilus influenzae type b meningitis.* J Infect Dis, 1987. **155**(2): p. 213-9.

262. Daum, R.S., et al., *Haemophilus influenzae type b vaccines: lessons from the past.* Pediatrics, 1988. **81**(6): p. 893-7.

263. Geme, J.W., 3rd, et al., *Consensus: management of Salmonella infection in the first year of life.* Pediatr Infect Dis J, 1988. **7**(9): p. 615-21.

264. Lebel, M.H., et al., *Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials.* N Engl J Med, 1988. **319**(15): p. 964-71.

265. Lebel, M.H. and G.H. McCracken, *Aztreonam: review of the clinical experience and potential uses in pediatrics.* Pediatr Infect Dis J, 1988. **7**(5): p. 331-9.

266. Madrigal, G., et al., *Single dose antibiotic therapy is not as effective as conventional regimens for management of acute urinary tract infections in children.* Pediatr Infect Dis J, 1988. **7**(5): p. 316-9.

267. McCracken, G.H., *Management of acute otitis media with effusion.* Pediatr Infect Dis J, 1988. **7**(6): p. 442-5.

268. Mustafa, M.M., M.H. Lebel, and G.H. McCracken, *Tenosynovitis and transient arthritis associated with Haemophilus influenzae type b bacteremia.* Pediatr Infect Dis J, 1988. **7**(7): p. 517-9.

269. Nelson, J.D. and G.H. McCracken, *Immunization and AIDS.* Pediatr Infect Dis J, 1988. **7**(6): p. 12.

270. Ramilo, O., B.T. Kinane, and G.H. McCracken, *Chloramphenicol neurotoxicity.* Pediatr Infect Dis J, 1988. **7**(5): p. 358-9.

271. Syrogiannopoulos, G.A., et al., *Haemophilus influenzae type b lipooligosaccharide induces meningeal inflammation.* J Infect Dis, 1988. **157**(2): p. 237-44.

272. Belman, A.B., et al., *Management of urinary tract infections.* Pediatr Infect Dis J, 1989. **8**(8): p. 560-3.

273. Feigin, R.D., et al., *Management of diarrheal illness.* Pediatr Infect Dis J, 1989. **8**(8): p. 579-82.

274. Lebel, M.H., M.J. Hoyt, and G.H. McCracken, *Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis.* J Pediatr, 1989. **114**(6): p. 1049-54.

275. Lebel, M.H., et al., *Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis.* Am J Dis Child, 1989. **143**(3): p. 301-6.

276. Lebel, M.H. and G.H. McCracken, *Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children.* Pediatrics, 1989. **83**(2): p. 161-7.

277. McCracken, G.H., *Current management of bacterial meningitis.* Pediatr Infect Dis J, 1989. **8**(12): p. 919-21.

278. McCracken, G.H., *Options in antimicrobial management of urinary tract infections in infants and children.* Pediatr Infect Dis J, 1989. **8**(8): p. 552-5.

279. McCracken, G.H. and M.H. Lebel, *Dexamethasone therapy for bacterial meningitis in infants and children.* Am J Dis Child, 1989. **143**(3): p. 287-9.

280. McCracken, G.H., et al., *Cerebrospinal fluid interleukin 1-beta and tumor necrosis factor concentrations and outcome from neonatal gram-negative enteric bacillary meningitis.* Pediatr Infect Dis J, 1989. **8**(3): p. 155-9.

281. Mertsola, J., et al., *Release of endotoxin after antibiotic treatment of Gram-negative bacterial meningitis.* Pediatr Infect Dis J, 1989. **8**(12): p. 904-6.

282. Mertsola, J., et al., *Specific detection of Haemophilus influenzae type b lipooligosaccharide by a polymyxin B monoclonal antibody assay.* J Immunol Methods, 1989. **122**(2): p. 219-26.

283. Mustafa, M.M., et al., *Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis.* J Pediatr, 1989. **115**(2): p. 208-13.

284. Mustafa, M.M. and G.H. McCracken, *Antimicrobial agents in pediatrics.* Infect Dis Clin North Am, 1989. **3**(3): p. 491-506.

285. Mustafa, M.M., et al., *Increased endotoxin and interleukin-1 beta concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy.* J Infect Dis, 1989. **160**(5): p. 891-5.

286. Mustafa, M.M., et al., *Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis.* J Infect Dis, 1989. **160**(5): p. 818-25.

287. Mustafa, M.M., et al., *Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis.* J Clin Invest, 1989. **84**(4): p. 1253-9.

288. Mustafa, M.M., et al., *Prostaglandins E2 and I2, interleukin 1-beta, and tumor necrosis factor in cerebrospinal fluid in infants and children with bacterial meningitis.* Pediatr Infect Dis J, 1989. **8**(12): p. 921-2.

289. Mustafa, M.M., et al., *Role of tumor necrosis factor alpha (cachectin) in experimental and clinical bacterial meningitis.* Pediatr Infect Dis J, 1989. **8**(12): p. 907-8.

290. Mustafa, M.M., et al., *Induction of meningeal inflammation by outer membrane vesicles of Haemophilus influenzae type b.* J Infect Dis, 1989. **159**(5): p. 917-22.

291. Patrick, C.C., et al., *Antigenic evidence for simultaneous expression of two different lipooligosaccharides by some strains of Haemophilus influenzae type b.* Infect Immun, 1989. **57**(7): p. 1971-8.

292. Pimm, S.L., et al., *Plausible alternatives to bottlenecks to explain reduced genetic diversity.* Trends in ecology & evolution, 1989. **4**(6): p. 176-8.

293. Ramilo, O., et al., *Role of interleukin 1-beta in meningeal inflammation.* Pediatr Infect Dis J, 1989. **8**(12): p. 909-10.

294. Saez-Llorens, X., et al., *Modulation of meningeal inflammation by treatment with pentoxifylline.* Pediatr Infect Dis J, 1989. **8**(12): p. 922-3.

295. Saez-Llorens, X.J., et al., *Brain abscess in infants and children.* Pediatr Infect Dis J, 1989. **8**(7): p. 449-58.

296. Sanchez, P.J., et al., *Molecular analysis of the fetal IgM response to Treponema pallidum antigens: implications for improved serodiagnosis of congenital syphilis.* J Infect Dis, 1989. **159**(3): p. 508-17.

297. Sande, M.A., et al., *Pathophysiology of bacterial meningitis: summary of the workshop.* Pediatr Infect Dis J, 1989. **8**(12): p. 929-33.

298. Tarlow, M.J. and G.H. McCracken, *Steroids in meningitis.* Br J Hosp Med, 1989. **42**(5): p. 358.

299. Cope, L.D., et al., *Effect of mutations in lipooligosaccharide biosynthesis genes on virulence of Haemophilus influenzae type b.* Infect Immun, 1990. **58**(7): p. 2343-51.

300. Mertsola, J., et al., *Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay.* J Clin Microbiol, 1990. **28**(12): p. 2700-6.

301. Mustafa, M.M., et al., *Cerebrospinal fluid prostaglandins, interleukin 1 beta, and tumor necrosis factor in bacterial meningitis. Clinical and laboratory correlations in placebo-treated and dexamethasone-treated patients.* Am J Dis Child, 1990. **144**(8): p. 883-7.

302. Mustafa, M.M., et al., *Acute hematogenous pelvic osteomyelitis in infants and children.* Pediatr Infect Dis J, 1990. **9**(6): p. 416-21.

303. Prober, C.G., et al., *Consensus: varicella-zoster infections in pregnancy and the perinatal period.* Pediatr Infect Dis J, 1990. **9**(12): p. 865-9.

304. Ramilo, O., et al., *Detection of interleukin 1 beta but not tumor necrosis factor-alpha in cerebrospinal fluid of children with aseptic meningitis.* Am J Dis Child, 1990. **144**(3): p. 349-52.

305. Ramilo, O., et al., *Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation.* J Exp Med, 1990. **172**(2): p. 497-507.

306. Saez-Llorens, X. and G.H. McCracken, *Bacterial meningitis in neonates and children.* Infect Dis Clin North Am, 1990. **4**(4): p. 623-44.

307. Saez-Llorens, X., et al., *Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.* Antimicrob Agents Chemother, 1990. **34**(5): p. 837-43.

308. Saez-Llorens, X., et al., *Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications.* J Pediatr, 1990. **116**(5): p. 671-84.

309. Umana, M.A., et al., *Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections.* Pediatr Infect Dis J, 1990. **9**(3): p. 175-80.

310. Waagner, D.C., et al., *Lack of adverse effects of dexamethasone therapy in aseptic meningitis.* Pediatr Infect Dis J, 1990. **9**(12): p. 922-3.

311. Cope, L.D., et al., *Molecular cloning of a gene involved in lipooligosaccharide biosynthesis and virulence expression by Haemophilus influenzae type B.* Mol Microbiol, 1991. **5**(5): p. 1113-24.

312. Grimprel, E., et al., *Use of polymerase chain reaction and rabbit infectivity testing to detect Treponema pallidum in amniotic fluid, fetal and neonatal sera, and cerebrospinal fluid.* J Clin Microbiol, 1991. **29**(8): p. 1711-8.

313. Jafari, H.S., et al., *Characteristics of experimental Candida albicans infection of the central nervous system in rabbits.* J Infect Dis, 1991. **164**(2): p. 389-95.

314. Jafari, H.S., et al., *Pharmacokinetics and antibacterial efficacy of cefpirome (HR 810) in experimental Escherichia coli and Haemophilus influenzae type b meningitis.* Antimicrob Agents Chemother, 1991. **35**(2): p. 220-3.

315. Kennedy, W.A., M.J. Hoyt, and G.H. McCracken, *The role of corticosteroid therapy in children with pneumococcal meningitis.* Am J Dis Child, 1991. **145**(12): p. 1374-8.

316. Mertsola, J., et al., *Detection of experimental Haemophilus influenzae type b bacteremia and endotoxemia by means of an immunolimulus assay.* J Infect Dis, 1991. **164**(2): p. 353-8.

317. Mertsola, J., et al., *In vivo and in vitro expression of Haemophilus influenzae type b lipooligosaccharide epitopes.* J Infect Dis, 1991. **164**(3): p. 555-63.

318. Mertsola, J., et al., *Endotoxin concentrations in cerebrospinal fluid correlate with clinical severity and neurologic outcome of Haemophilus influenzae type B meningitis.* Am J Dis Child, 1991. **145**(10): p. 1099-103.

319. Odio, C.M., et al., *The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis.* N Engl J Med, 1991. **324**(22): p. 1525-31.

320. Saez-Llorens, X., et al., *Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-alpha, and interleukin-1 beta.* J Infect Dis, 1991. **163**(6): p. 1267-72.

321. Saez-Llorens, X., et al., *Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis.* J Clin Invest, 1991. **88**(6): p. 2003-11.

322. Saez-Llorens, X. and G.H. McCracken, *Mediators of meningitis: therapeutic implications.* Hosp Pract (Off Ed), 1991. **26**(1): p. 68-77.

323. Uauy, R., et al., *Metabolic tolerance to arginine: implications for the safe use of arginine salt-aztreonam combination in the neonatal period.* J Pediatr, 1991. **118**(6): p. 965-70.

324. Velasco, S., et al., *Temperature-dependent modulation of lipopolysaccharide-induced interleukin-1 beta and tumor necrosis factor alpha expression in cultured human astroglial cells by dexamethasone and indomethacin.* J Clin Invest, 1991. **87**(5): p. 1674-80.

325. Feigin, R.D., G.H. McCracken, and J.O. Klein, *Diagnosis and management of meningitis.* Pediatr Infect Dis J, 1992. **11**(9): p. 785-814.

326. Friedland, I.R., et al., *Cranial computed tomographic scans have little impact on management of bacterial meningitis.* Am J Dis Child, 1992. **146**(12): p. 1484-7.

327. Gibbs, R.S., et al., *Consensus: perinatal prophylaxis for group B streptococcal infection.* Pediatr Infect Dis J, 1992. **11**(3): p. 179-83.

328. Jafari, H.S. and G.H. McCracken, *Sepsis and septic shock: a review for clinicians.* Pediatr Infect Dis J, 1992. **11**(9): p. 739-48.

329. Lentnek, A., et al., *Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Infectious Diseases Society of America and the Food and Drug Administration.* Clin Infect Dis, 1992. **15 Suppl 1**: p. S189-94.

330. McCracken, G.H., *Current management of bacterial meningitis in infants and children.* Pediatr Infect Dis J, 1992. **11**(2): p. 169-74.

331. McCracken, G.H., et al., *Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis. Infectious Diseases Society of America and the Food and Drug Administration.* Clin Infect Dis, 1992. **15 Suppl 1**: p. S182-8.

332. Sande, M.A., et al., *Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis. Infectious Diseases Society of America and the Food and Drug Administration.* Clin Infect Dis, 1992. **15 Suppl 1**: p. S200-5.

333. Unhanand, M., et al., *Pulmonary clearance of Moraxella catarrhalis in an animal model.* J Infect Dis, 1992. **165**(4): p. 644-50.

334. Whitley, R.J., et al., *Evaluation of new anti-infective drugs for the treatment of viral encephalitis. Infectious Diseases Society of America and the Food and Drug Administration.* Clin Infect Dis, 1992. **15 Suppl 1**: p. S195-9.

335. Baraff, L.J., et al., *Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research.* Ann Emerg Med, 1993. **22**(7): p. 1198-210.

336. Friedland, I.R., et al., *Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis.* J Infect Dis, 1993. **168**(3): p. 657-62.

337. Friedland, I.R., et al., *Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 1993. **37**(8): p. 1630-6.

338. Friedland, I.R., S. Shelton, and G.H. McCracken, *Chloramphenicol in penicillin-resistant pneumococcal meningitis.* Lancet, 1993. **342**(8865): p. 240-1.

339. Friedland, I.R., S. Shelton, and G.H. McCracken, *Screening for cephalosporin-resistant Streptococcus pneumoniae with the Kirby-Bauer disk susceptibility test.* J Clin Microbiol, 1993. **31**(6): p. 1619-21.

340. Friedland, I.R., et al., *Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.* Pediatr Infect Dis J, 1993. **12**(3): p. 196-200.

341. Helminen, M.E., et al., *A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.* Infect Immun, 1993. **61**(5): p. 2003-10.

342. Helminen, M.E., et al., *A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo.* J Infect Dis, 1993. **168**(5): p. 1194-201.

343. Jafari, H.S., et al., *Dexamethasone attenuation of cytokine-mediated articular cartilage degradation in experimental acute lapine Haemophilus arthritis.* J Infect Dis, 1993. **168**: p. 1186-93.

344. Maciver, I., et al., *Effect of immunization of pulmonary clearance of Moraxella catarrhalis in an animal model.* J Infect Dis, 1993. **168**(2): p. 469-72.

345. McCracken, G.L., *Clinical joint sound analysis.* Cranio, 1993. **11**(3): p. 240-2.

346. Saez-Llorens, X. and G.H. McCracken, *Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management.* J Pediatr, 1993. **123**(4): p. 497-508.

347. Saxen, H., et al., *Detection of enterobacterial lipopolysaccharides and experimental endotoxemia by means of an immunolimulus assay using both serotype-specific and cross-reactive antibodies.* J Infect Dis, 1993. **168**(2): p. 393-9.

348. Unhanand, M., et al., *Gram-negative enteric bacillary meningitis: a twenty-one-year experience.* J Pediatr, 1993. **122**(1): p. 15-21.

349. Friedland, I.R. and G.H. McCracken, *Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.* N Engl J Med, 1994. **331**(6): p. 377-82.

350. Friedland, I.R., et al., *Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae.* J Antimicrob Chemother, 1994. **34**(2): p. 231-7.

351. Friedland, I.R., S. Shelton, and G.H. McCracken, *Screening for cephalosporin-resistant Streptococcus pneumoniae with the Kirby-Bauer disk susceptibility test.* J Clin Microbiol, 1994. **32**(1): p. 274-5.

352. Helminen, M.E., et al., *A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies.* J Infect Dis, 1994. **170**(4): p. 867-72.

353. Jafari, H.S. and G.H. McCracken, *Dexamethasone therapy in bacterial meningitis.* Pediatr Ann, 1994. **23**(2): p. 82-8.

354. Jafari, H.S., et al., *Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.* Antimicrob Agents Chemother, 1994. **38**(1): p. 83-9.

355. McCracken, G.H., *Considerations in selecting an antibiotic for treatment of acute otitis media.* Pediatr Infect Dis J, 1994. **13**(11): p. 1054-7.

356. Paris, M.M., et al., *Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 1994. **38**(6): p. 1320-4.

357. Trujillo, M. and G.H. McCracken, *Prolonged morbidity in children with group A beta-hemolytic streptococcal pneumonia.* Pediatr Infect Dis J, 1994. **13**(5): p. 411-2.

358. Donald, P.R., et al., *Concentrations of interferon gamma, tumor necrosis factor alpha, and interleukin-1 beta in the cerebrospinal fluid of children treated for tuberculous meningitis.* Clin Infect Dis, 1995. **21**(4): p. 924-9.

359. Friedland, I.R., et al., *The limited role of pneumolysin in the pathogenesis of pneumococcal meningitis.* J Infect Dis, 1995. **172**(3): p. 805-9.

360. Kimberlin, D.W., et al., *Modulation of expression of genes involved in the inflammatory response by lipopolysaccharide and temperature in cultured human astroglial cells.* Immunol Invest, 1995. **24**(5): p. 775-85.

361. Kimberlin, D.W., et al., *Protein synthesis-dependent induction of interleukin-1 beta by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cells.* J Clin Immunol, 1995. **15**(4): p. 199-204.

362. McCracken, G.H., *Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics.* Pediatr Infect Dis J, 1995. **14**(5): p. 424-8.

363. Paris, M.M., et al., *Effect of interleukin-1 receptor antagonist and soluble tumor necrosis factor receptor in animal models of infection.* J Infect Dis, 1995. **171**(1): p. 161-9.

364. Paris, M.M., et al., *Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 1995. **39**(6): p. 1243-6.

365. Paris, M.M., O. Ramilo, and G.H. McCracken, *Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.* Antimicrob Agents Chemother, 1995. **39**(10): p. 2171-5.

366. Saez-Llorens, X., et al., *Intrapartum prophylaxis with ceftriaxone decreases rates of bacterial colonization and early-onset infection in newborns.* Clin Infect Dis, 1995. **21**(4): p. 876-80.

367. Saez-Llorens, X., et al., *Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children.* Antimicrob Agents Chemother, 1995. **39**(4): p. 937-40.

368. Schaad, U.B., S.L. Kaplan, and G.H. McCracken, *Steroid therapy for bacterial meningitis.* Clin Infect Dis, 1995. **20**(3): p. 685-90.

369. Aebi, C., et al., *Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin.* Infect Immun, 1996. **64**(6): p. 2024-30.

370. Ahmed, A., et al., *Cerebrospinal fluid values in the term neonate.* Pediatr Infect Dis J, 1996. **15**(4): p. 298-303.

371. McCracken, G.A., C.V. Washington, and S.F. Templeton, *Metastatic cutaneous carcinoid.* Journal of the American Academy of Dermatology, 1996. **35**(6): p. 997-8.

372. Paris, M.M., et al., *Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.* Antimicrob Agents Chemother, 1996. **40**(1): p. 122-6.

373. Singer, A.J., et al., *Correlation among clinical, laboratory, and hepatobiliary scanning findings in patients with suspected acute cholecystitis.* Ann Emerg Med, 1996. **28**(3): p. 267-72.

374. Slusher, T., et al., *Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis.* Pediatr Infect Dis J, 1996. **15**(7): p. 579-83.

375. Trujillo, M., et al., *Safety and efficacy of cefprozil as part of a parenteral-oral antibiotic regimen for the treatment of suppurative skeletal infections in children.* Clin Infect Dis, 1996. **23**(4): p. 843.

376. Aebi, C., et al., *Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration.* J Pediatr, 1997. **130**(4): p. 612-5.

377. Aebi, C., et al., *A protective epitope of Moraxella catarrhalis is encoded by two different genes.* Infect Immun, 1997. **65**(11): p. 4367-77.

378. Ahmed, A., et al., *Clinical utility of the polymerase chain reaction for diagnosis of enteroviral meningitis in infancy.* J Pediatr, 1997. **131**(3): p. 393-7.

379. Ahmed, A., et al., *Once-daily gentamicin therapy for experimental Escherichia coli meningitis.* Antimicrob Agents Chemother, 1997. **41**(1): p. 49-53.

380. Baraff, L.J., et al., *Management of the young febrile child. Commentary on practice guidelines.* Pediatrics, 1997. **100**(1): p. 134-6.

381. Lutsar, I., et al., *Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 1997. **41**(11): p. 2414-7.

382. McCracken, G.H., *Microbiologic activity of the newer macrolide antibiotics.* Pediatr Infect Dis J, 1997. **16**(4): p. 432-7.

383. Paris, M.M., et al., *The effect of interleukin-10 on meningeal inflammation in experimental bacterial meningitis.* J Infect Dis, 1997. **176**(5): p. 1239-46.

384. Rotbart, H.A., et al., *Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types.* Pediatr Infect Dis J, 1997. **16**(4): p. 409-11.

385. Seikel, K., S. Shelton, and G.H. McCracken, *Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media.* Pediatr Infect Dis J, 1997. **16**(7): p. 710-1.

386. Aebi, C., et al., *Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis.* Infect Immun, 1998. **66**(2): p. 540-8.

387. Aebi, C., et al., *Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E.* Infect Immun, 1998. **66**(7): p. 3113-9.

388. Lutsar, I., et al., *Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 1998. **42**(10): p. 2650-5.

389. Lutsar, I., G.H. McCracken, and I.R. Friedland, *Antibiotic pharmacodynamics in cerebrospinal fluid.* Clin Infect Dis, 1998. **27**(5): p. 1117-27, quiz 1128-9.

390. McCracken, G.H., *Treatment of acute otitis media in an era of increasing microbial resistance.* Pediatr Infect Dis J, 1998. **17**(6): p. 576-9; discussion 580.

391. Mustafa, M.M., et al., *Immune recovery in children with malignancy after cessation of chemotherapy.* J Pediatr Hematol Oncol, 1998. **20**(5): p. 451-7.

392. Nelson, J.D. and G.H. McCracken, *Use of ticarcillin/clavulanate (Timentin) in the management of pediatric infections. Introduction.* Pediatr Infect Dis J, 1998. **17**(12): p. 1183-4.

393. Saez-Llorens, X., et al., *[Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].* Rev Med Panama, 1998. **23**(2): p. 27-33.

394. Seikel, K., S. Shelton, and G.H. McCracken, *Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media.* Pediatr Infect Dis J, 1998. **17**(10): p. 969-70.

395. Wubbel, L., et al., *Mycoplasma pneumoniae pneumonia in a mouse model.* J Infect Dis, 1998. **178**(5): p. 1526-9.

396. Wubbel, L. and G.H. McCracken, *Management of bacterial meningitis: 1998.* Pediatr Rev, 1998. **19**(3): p. 78-84.

397. Ahmed, A., et al., *Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 1999. **43**(4): p. 876-81.

398. Cope, L.D., et al., *Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products.* J Bacteriol, 1999. **181**(13): p. 4026-34.

399. Ghaffar, F., et al., *Increased carriage of resistant non-pneumococcal alpha-hemolytic streptococci after antibiotic therapy.* J Pediatr, 1999. **135**(5): p. 618-23.

400. Ghaffar, F., I.R. Friedland, and G.H. McCracken, *Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae.* Pediatr Infect Dis J, 1999. **18**(7): p. 638-46.

401. Heasman, P.A. and G.I. McCracken, *Powered toothbrushes: a review of clinical trials.* Journal of clinical periodontology, 1999. **26**(7): p. 407-20.

402. Hollander, J.E., et al., *Emergency department observation of poisoned patients: how long is necessary?* Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1999. **6**(9): p. 887-94.

403. Jafri, H.S. and G.H. McCracken, *Fluoroquinolones in paediatrics.* Drugs, 1999. **58 Suppl 2**: p. 43-8.

404. Klein, J.O. and G.H. McCracken, *Acute otitis media: a treatment paradigm for the new millenium. Introduction.* Pediatr Infect Dis J, 1999. **18**(12): p. 1119.

405. Lutsar, I., et al., *Efficacy of gatifloxacin in experimental Escherichia coli meningitis.* Antimicrob Agents Chemother, 1999. **43**(7): p. 1805-7.

406. McCoig, C.C., et al., *Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.* J Antimicrob Chemother, 1999. **43**(5): p. 683-8.

407. McCracken, G.F., G.M. Burghardt, and S.E. Houts, *Microsatellite markers and multiple paternity in the garter snake thamnophis sirtalis.* Molecular ecology, 1999. **8**(9): p. 1475-9.

408. McCracken, G.H., *Prescribing antimicrobial agents for treatment of acute otitis media.* Pediatr Infect Dis J, 1999. **18**(12): p. 1141-6.

409. Ng, W., et al., *Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.* J Antimicrob Chemother, 1999. **43**(6): p. 811-6.

410. Odio, C.M., et al., *Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group.* Pediatr Infect Dis J, 1999. **18**(7): p. 581-90.

411. Rotbart, H.A., et al., *Clinical significance of enteroviruses in serious summer febrile illnesses of children.* Pediatr Infect Dis J, 1999. **18**(10): p. 869-74.

412. Saez-Llorens, X. and G.H. McCracken, *Antimicrobial and anti-inflammatory treatment of bacterial meningitis.* Infect Dis Clin North Am, 1999. **13**(3): p. 619-36, vii.

413. Weber, M.W., et al., *Chloramphenicol pharmacokinetics in infants less than three months of age in the Philippines and The Gambia.* Pediatr Infect Dis J, 1999. **18**(10): p. 896-901.

414. Wubbel, L., et al., *Etiology and treatment of community-acquired pneumonia in ambulatory children.* Pediatr Infect Dis J, 1999. **18**(2): p. 98-104.

415. Ghaffar, F., et al., *Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.* Clin Infect Dis, 2000. **31**(4): p. 875-80.

416. Klein, J.O. and G.H. McCracken, *Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children.* Pediatr Infect Dis J, 2000. **19**(12 Suppl): p. S181-3.

417. Lafontaine, E.R., et al., *The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro.* J Bacteriol, 2000. **182**(5): p. 1364-73.

418. McCracken, G.H., *Diagnosis and management of pneumonia in children.* Pediatr Infect Dis J, 2000. **19**(9): p. 924-8.

419. McCracken, G.H., *Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.* Clin Infect Dis, 2000. **31 Suppl 2**: p. S45-50.

420. McCracken, G.H., *Etiology and treatment of pneumonia.* Pediatr Infect Dis J, 2000. **19**(4): p. 373-7.

421. McCracken, G.I., et al., *Testing the efficacy of plaque removal of a prototype brush head for a powered toothbrush.* J Clin Periodontol, 2000. **27**(8): p. 542-8.

422. Michelow, I.C., et al., *Abiotrophia spp. brain abscess in a child with Down's syndrome.* Pediatr Infect Dis J, 2000. **19**(8): p. 760-3.

423. Ng, W., et al., *Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia.* Apmis, 2000. **108**(11): p. 729-33.

424. Trujillo, M., et al., *Cefprozil concentrations in middle ear fluid of children with acute otitis media.* Pediatr Infect Dis J, 2000. **19**(3): p. 268-70.

425. Ghaffar, F.A., M. Wordemann, and G.H. McCracken, *Acute mastoiditis in children: a seventeen-year experience in Dallas, Texas.* Pediatr Infect Dis J, 2001. **20**(4): p. 376-80.

426. Hardy, R.D., et al., *Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.* Infect Immun, 2001. **69**(6): p. 3869-76.

427. Klein, J.O. and G.H. McCracken, *The use of topical ofloxacin for otic diseases in infants and children. Summary and conclusions.* Pediatr Infect Dis J, 2001. **20**(1): p. 123-5.

428. McCracken, G.H., *Clinical practice guidelines for the diagnosis and treatment of respiratory tract infections.* Am J Manag Care, 2001. **7**(6 Suppl): p. S183-91.

429. McCracken, G.I., et al., *A comparative study of two powered toothbrushes and one manual toothbrush in young adults.* J Clin Dent, 2001. **12**(1): p. 7-10.

430. Mustafa, M.M., et al., *Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.* Pediatr Infect Dis J, 2001. **20**(3): p. 362-9.

431. Rodriguez-Cerrato, V., et al., *BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.* Antimicrob Agents Chemother, 2001. **45**(11): p. 3098-103.

432. Rodriguez-Cerrato, V., et al., *Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.* Antimicrob Agents Chemother, 2001. **45**(11): p. 3092-7.

433. Dagan, R. and G.H. McCracken, *Flaws in design and conduct of clinical trials in acute otitis media.* Pediatr Infect Dis J, 2002. **21**(10): p. 894-902.

434. Ghaffar, F., et al., *Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media.* Clin Infect Dis, 2002. **34**(10): p. 1301-9.

435. Hardy, R.D., et al., *Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease.* Infect Immun, 2002. **70**(2): p. 649-54.

436. McCracken, G.H., *Rich nations, poor nations, and bacterial meningitis.* Lancet, 2002. **360**(9328): p. 183.

437. McCracken, G.H., *Diagnosis and management of acute otitis media in the urgent care setting.* Ann Emerg Med, 2002. **39**(4): p. 413-21.

438. Michelow, I.C., et al., *Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection.* Clin Infect Dis, 2002. **34**(1): p. E1-11.

439. Saez-Llorens, X., et al., *Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.* Pediatr Infect Dis J, 2002. **21**(1): p. 14-22.

440. Hardy, R.D., et al., *Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of Mycoplasma pneumoniae-Induced Pneumonia.* Antimicrob Agents Chemother, 2003. **47**(5): p. 1614-20.

441. Lutsar, I., et al., *Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis.* J Antimicrob Chemother, 2003. **52**(4): p. 651-5.

442. Rodriguez-Cerrato, V., et al., *Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.* Antimicrob Agents Chemother, 2003. **47**(1): p. 211-5.

443. Saez-Llorens, X. and G.H. McCracken, Jr., *Bacterial meningitis in children.* Lancet, 2003. **361**(9375): p. 2139-48.

444. Fonseca-Aten, M., et al., *Mycoplasma pneumoniae Induces Host-Dependent Pulmonary Inflammation and Airway Obstruction in Mice.* Am J Respir Cell Mol Biol, 2004.

445. Ghaffar, F., et al., *Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life.* Clin Infect Dis, 2004. **39**(7): p. 930-8.

446. Lee, M.C., et al., *Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.* Pediatr Infect Dis J, 2004. **23**(2): p. 123-7.

447. McCracken, G., J. McGeagh, and R. Roberts, *Antenatal HIV testing: evaluation of uptake and women's attitudes in a low risk population.* The Ulster medical journal, 2004. **73**(2): p. 92-5.

448. McCracken, G.H., Jr., *Current management of bacterial meningitis.* Adv Exp Med Biol, 2004. **549**: p. 31-3.

449. Michelow, I.C., et al., *Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community-acquired pneumonia.* J Clin Microbiol, 2004. **42**(7): p. 3339-41.

450. Michelow, I.C., et al., *Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children.* Pediatrics, 2004. **113**(4): p. 701-7.

451. Rios, A.M., et al., *Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.* Antimicrob Agents Chemother, 2004. **48**(8): p. 2897-904.

452. Chavez-Bueno, S., et al., *Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas.* Antimicrob Agents Chemother, 2005. **49**(6): p. 2283-8.

453. Chavez-Bueno, S. and G.H. McCracken, Jr., *Bacterial meningitis in children.* Pediatr Clin North Am, 2005. **52**(3): p. 795-810, vii.

454. Fonseca-Aten, M., et al., *Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice.* Am J Respir Cell Mol Biol, 2005. **32**(3): p. 201-10.

455. Fonseca-Aten, M., et al., *Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.* Antimicrob Agents Chemother, 2005. **49**(10): p. 4128-36.

456. McCracken, G., et al., *Assessing adherence with toothbrushing instructions using a data logger toothbrush.* British dental journal, 2005. **198**(1): p. 29-32; discussion 24.

457. McCracken, G.I., et al., *The crossover design to evaluate the efficacy of plaque removal in tooth-brushing studies.* J Clin Periodontol, 2005. **32**(11): p. 1157-62.

458. Rios, A.M., et al., *Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.* Antimicrob Agents Chemother, 2005. **49**(9): p. 3970-3.

459. Bowlware, K.L., et al., *Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily.* Pediatr Infect Dis J, 2006. **25**(3): p. 208-10.

460. Fonseca-Aten, M., et al., *Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.* Ann Allergy Asthma Immunol, 2006. **97**(4): p. 457-63.

461. Fonseca-Aten, M., et al., *Treatment of experimental chronic pulmonary mycoplasmosis.* Int J Antimicrob Agents, 2006. **28**(3): p. 253-8.

462. Ryan, M. and G.H. McCracken, Jr., *Evidence behind the WHO guidelines: hospital care for children.* J Trop Pediatr, 2006. **52**(1): p. 46-8.

463. Ardura, M.I., et al., *Daptomycin therapy for invasive Gram-positive bacterial infections in children.* Pediatr Infect Dis J, 2007. **26**(12): p. 1128-32.

464. Bogdanovich, T., et al., *Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.* Diagn Microbiol Infect Dis, 2007.

465. Messina, A.F., et al., *Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.* Pediatr Infect Dis J, 2007. **26**(6): p. 461-7.

466. Michelow, I.C., et al., *Systemic cytokine profile in children with community-acquired pneumonia.* Pediatr Pulmonol, 2007. **42**(7): p. 640-5.

467. Saez-Llorens, X. and G.H. McCracken, Jr., *Glycerol and bacterial meningitis.* Clin Infect Dis, 2007. **45**(10): p. 1287-9.

468. Salvatore, C.M., et al., *Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.* Infect Immun, 2007. **75**(1): p. 236-42.

469. Bradley, J.S. and G.H. McCracken, *Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.* Clin Infect Dis, 2008. **47 Suppl 3**: p. S241-8.

470. McCracken, G.H., *The antibiotic pipeline in pediatrics.* Adv Exp Med Biol, 2009. **634**: p. 147-51.

471. Nelson, J.D. and G.H. McCracken, Jr., *The pediatric infectious disease journal(r) newsletter: march 2009.* Pediatr Infect Dis J, 2009. **28**(3): p. A5-6.

472. Salvatore, C.M., et al., *Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.* Antimicrob Agents Chemother, 2009. **53**(4): p. 1546-51.

473. Santos, R.P., et al., *Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.* Pediatr Pulmonol, 2009. **44**(2): p. 148-54.

474. Techasaensiri, B., et al., *Viral coinfections in children with invasive pneumococcal disease.* Pediatr Infect Dis J, 2010. **29**(6): p. 519-23.

475. Techasaensiri, C., et al., *Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.* The Pediatric Infect Dis J, 2010. **29**(4): p. 294-300.

476. Bradley, J.S., et al., *Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.* Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. **53**(7): p. 617-30.

477. Bradley, J.S., et al., *The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.* Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. **53**(7): p. e25-76.

478. Greer, L.G., et al., *Pharmacokinetics of oseltamivir according to trimester of pregnancy.* American journal of obstetrics and gynecology, 2011. **204**(6 Suppl 1): p. S89-93.

479. Greer, L.G., et al., *Pharmacokinetics of oseltamivir in breast milk and maternal plasma.* American journal of obstetrics and gynecology, 2011. **204**(6): p. 524 e1-4.

 1. Eichenwald HF, McCracken GH and Kindberg S: Viral disease of the fetus, prema­ture and full-term infant. Progress in Medical Virology 1967; 9: 35-104.

 2. Eichenwald HF and McCracken GH: Systemic Antimicrobial Therapy in Shirkey H, Pediatric Therapy, 1968-69, 3rd Edition, pp 357-373.

 3. McCracken GH and Eichenwald HF: Infections of The Respiratory Tract in Nelson, W Textbook of Pediatrics, 9th Edition, pp 883-944, 1970.

 4. McCracken GH and Eichenwald HF: Systemic Antimicrobial Therapy in Shirkey, H. Pediatric Therapy, 4th Edition, 1969-1970.

 5. McCracken GH and Eichenwald HF: Neonatal Septicemia, in Barnett, HL, Pediatrics, 15th Edition, 1972.

 6. McCracken GH and Eichenwald HF: Neonatal Sepsis, Meningitis and Pneumonia, in Gillis SS and Kagan BM, Current Pediatric Therapy, 1972.

 7. McCracken GH: Antibiotics in the practice of pediatrics. Pediatric Portfolio 1, No. 10, July 19, 1971.

 8. McCracken GH and Marshall FN: Tetanus, in Gellis S and Kagan B, Current Pediat­ric Therapy 1974; 6: 550-554.

 9. McCracken GH: Neonatal Sepsis, Meningitis and Pneumonia, in Gellis S and Kagan B, Current Pediatric Therapy 1974; 6: 550-554.

10. McCracken GH: The changing pattern of neonatal bacterial infections: Therapeutic considerations in current concepts in the management of Gram-negative bacterial infections. Excerpta Medica International Congress Series No. 318, pp 3-8, 1974.

11. Kaplan JM and McCracken GH: Bacterial and Viral Infections of The Newborn, in Avery GC, Neonatology, p 537-560, JB Lippincott Co, Philadelphia, PA.

12. McCracken GH: Antimicrobial Therapy in The Newborn Infant, in Kagan B, Antimicro­bial Therapy, p 195-204, 1974, WB Saunders.

13. Robbins JB, Schneerson R, Liu TY, Schiffer MS, Schiffman G, Myerowitz RL, McCracken GH, Orskov I and Orskov F: Cross-reacting bacterial antigens and immunity to disease caused by encapsulated bacteria. The Immune System and Infectious Disease, IV International Convocation of Immunology, Buffalo, NY, pp 218-241, 1974.

14. McCracken GH: Neonatal septicemia and meningitis. Hosp Pract 1976; 11: 49.

15. McCracken GH: Managing neonatal infections. Hosp Pract 1976; 11: 89.

16. McCracken GH and Eichenwald HF: All chapters on upper and lower respiratory tract diseases in Textbook of Pediatrics, Vaughan V and McKay RJ, 10th Edition, 1975.

17. Eichenwald HF and McCracken GH: Antimicrobial Therapy, in Pediatric Therapy, Shirkey H, 5th Edition, CV Mosby Co, 1976.

18. McCracken GH and Howard JB: Bacterial Infections of The Newborn, in Schaffer AJ and Avery M, Diseases of The Newborn, 4th Edition, 1976.

19. McCracken GH: Clinical Pharmacology of Antibacterial Agents, in Remington JS and Klein JO, Infectious Diseases of The Fetus and Newborn Infant, WB Saunders, Philadelphia, p 1020, 1976.

20. McCracken GH and Nelson JD: Antimicrobial Therapy for Newborns: Practical Application of Pharmacology To Clinical Usage. Grune and Stratton, New York, 1977.

21. McCracken GH: Neonatal Septicemia, Meningitis and Pneumonia, in Gellis S and Kagan B, Current Pediatric Therapy, Volume 8, WB Saunders, Philadelphia, PA, 1978, pp 531-536.

22. Wientzen RL and McCracken GH: Pathogenesis and management of neonatal sepsis and meningitis. Current Problems in Pediatrics, Volume VIII, (No. 2), 1977.

23. McCracken GH and Nelson JD: Infantile Enteric Bacillary Meningitis, in Handbook of Clinical Neurology, Volume 33: 61-68 (Chapter 5), 1978.

24. McCracken GH: Lung abscess in children. Hospital Practice 1978; Aug.:35-36.

25. McCracken GH: Septic arthritis in a neonate. Hospital Pract 1979; 14: 158-164.

26. Glode MP, Robbins JB and McCracken GH: Rapid Diagnosis of Neonatal Infections, in Rytel MW, Rapid Diagnosis in Infectious Disease, CRC Press, Inc., Boca Raton, FL, 1979, 1979, p 131.

27. McCracken GH: Neonatal Septicemia, Meningitis and Pneumonia, in Gellis S and Kagan B, Current Pediatric Therapy, Vol. 9, WB Saunders Co., Philadelphia, PA, 1980.

28. McCracken GH: Perinatal Bacterial Diseases, in Feigin RD and Cherry JD, Textbook of Pediatric Infectious Diseases, WB Saunders Co., Philadelphia, PA, 1981.

29. Eichenwald HF and McCracken GH: Systemic Antimicrobial Therapy, in Shirkey HC, Pediatric Therapy, Vol. 6, CV Mosby, St. Louis, MO, 1980, p 327-347.

30. McCracken GH: Septicemia, Meningitis and Pneumonia in Newborn Infants, in Shirkey HC, Pediatric Therapy, Vol. 6, CV Mosby, St. Louis, MO, 1980, pp 393-398.

31. Siegel JD and McCracken GH: Aminoglycosides in Pediatrics, in The Aminoglycosides, Whelton A and Neu HC (Eds.), Marcel Dekker, Inc., New York, NY, 1982, pp 527-555.

32. McCracken GH: Pharmacology of new cephalosporins and related compounds in infants and children in Neu HC, New Beta-Lactam Antibiotics: A review from Chemistry to Clinical Efficacy of The New Cephalosporins, College of Physicians of Philadelphia, Philadelphia, PA, 1982, p. 171-176.

33. Siegel JD and McCracken GH: Neonatal Septicemia and Meningitis, in Rudolph AM, Pediatrics, 17th Ed., Appleton-Century-Crofts. Norwalk, CT, 1982, pp 511-151.

34. McCracken GH and Siegel JD: Clinical Pharmacology of Antimicrobial Therapy, in Remington JS and Klein JO, Infectious Diseases of the Fetus and Newborn Infant, 2nd Ed. WB Saunders Co., Philadelphia, 1983, pp 1053-1095.

35. McCracken GH: New Developments In The Management of Neonatal Meningitis, in Sande M, Smith A and Root R (Ed), Bacterial Meningitis, Churchill Livingston, New York, 1985, pp 159-166.

36. Nelson JD and McCracken GH: Clinical Reviews in Pediatric Infectious Disease. B.C. Decker, Inc., Toronto, 1985.

37. McCracken GH: Comparative Evaluation of The Aminopenicillins For Oral Use, in JD Nelson and GH McCracken, Clinical Reviews of Pediatric Infectious Disease, B.C. Decker, Inc., Toronto, 1985, pp 73-77.

38. McCracken GH and Nelson JD: The Third Generation Cephalosporins and The Pediat­ric Practitioner, in JD Nelson and GH McCracken, Clinical Reviews in Pediatric Infectious Disease, B.C. Decker, Inc., Toronto, 1985, pp 79-83.

39. Nelson JD and McCracken GH: Anti-Pseudomonas Penicillins, in JD Nelson and GH McCracken, Clinical Reviews in Pediatric Infectious Disease, B.C. Decker, Inc., Toronto, 1985, pp 85-88.

40. McCracken GH: Use of the new cephalosporins in pediatrics. Excerpta Medical (Congress Series No. 48), June, 1985, pp 15-18.

41. McCracken GH: Aspiration Pneumonia and Lung Abscess, in Nelson JD, Current Therapy in Pediatric Infectious Disease, CV Mosby Co., St. Louis, 1986, pp 41-42.

42. McCracken GH: Pyomyositis, in Nelson JD, Current Therapy in Pediatric Infectious Disease, CV Mosby Co., St. Louis, 1986, pp 73-74.

43. McCracken GH: Subdural Empyema, in Nelson JD, Current Therapy in Pediatric Infectious Disease, CV Mosby Co., St. Louis, 1986, p 113.

44. McCracken GH: Cystitis and Pyelonephritis, in Nelson JD, Current Therapy in Pediatric Infectious Disease, CV Mosby Co., St. Louis, 1986, pp 128.

45. McCracken GH and Freij BJ: Perinatal Bacterial Diseases in Feigin R and Cherry J, Textbook of Pediatric Infectious Diseases, 2nd Edition, W.B. Saunders Co., Philadelphia, 1987, pp. 940-966.

46. McCracken GM and Freij BJ: Neonatal septicemia and meningitis in Abraham M. Rudolph. Pediatrics, 18th Edition, Appleton & Lange, California, 1987, pp. 479-485.

47. Mustafa MM, McCracken GH, Jr: Antimicrobial agents in pediatrics. Infectious Disease Clinic of N America 1989; 3: 491-506.

48. Sáez-Llorens X and McCracken GH Jr: Bacterial meningitis in neonates and children. Inf Dis Clin NA 1990; 4: 623-644.

49. Sáez-Llorens X, McCracken GH, Jr: Mediators of meningitis: Therapeutic implications. Hosp Prac 1991; 26: 68-77.

50. Sáez-Llorens X, McCracken GH: Molecular pathophysiology of meningitis. In T.J. David ed. Recent Advances in Pediatrics. Vol. 12, 1993.

51. Jafari HS, McCracken GH: Dexamethasone therapy in bacterial meningitis. Pediatr Ann 1994;23: 82.

52. Hickey SM, McCracken GH: Postnatal bacterial infections; fungal and protozoan infections. In Fanaroff AA and Martin RJ, ed. Neonatal-Perinatal Medicine. Sixth edition. Mosby St. Louis, 1997.

53. Sáez-Llorens X, McCracken GH: Genesis of fever and the inflammatory response. In Long SS, Pickering LK, Prober CG ed. Principles and Practices of Pediatric Infectious Diseases. Churchill Livingstone. New York 1997.

54. Sáez-Llorens X, McCracken GH: Septicemia and septic shock. In Long SS, Pickering LK, Prober CG ed. Principles and Practices of Pediatric Infectious Diseases. Churchill Livingstone. New York 1997.

55. Cetron MS, Farley MM, McCracken GH: Multidrug-resistant *S. pneumonaie*: What can be done? Patient Care, January 15, 1997.

56. Wubbel L, McCracken GH: Management of bacterial meningitis: 1998. Pediatrics in Review, 1998;19:78-84.

57. Hickey SM, McCracken GH: Antibacterial Therapeutic Agents. In Feigin RD and Cherry JD. Textbook of Pediatric Infectious Diseases. 4th Edition. W.B. Saunders Co. Phildelphia, 1998, p. 2164.

58. Sáez-Llorens X, McCracken GH: Perinatal Bacterial Diseases. In Feigin RD and Cherry JD. Textbook of Pediatric Infectious Diseases. 4th Edition. W.B. Saunders Co. Philadelphia, 1998, p. 892.

59. Sáez-Llorens X, McCracken GH: Meningitis. In Katz SL, Gershon AA, Hotez PJ. Krugman's Infectious Diseases of Children. Mosby. St. Louis, 1998, p. 265.

1. Sáez-Llorens X, McCracken GH: Antimicrobial and Anti-Inflammatory Treatment of Bacterial Meningitis. Infectious Disease Clinics of North America. 1999, p. 619.
2. Sáez-Llorens X, McCracken GH: Meningitis. In Gershon AA, Hotez PJ, Katz SL. Infectious

Diseases of Children. 11th Edition. Mosby. St. Louis, 2004, p. 373.

62. Ghaffar F, McCracken GH. Quinolones in pediatrics. In Hooper DC, Rubinstein E. Quinolone

 Antomicrobial Agents. 3rd Edition. ASM Press. Washington, DC, 2003, p.343.

 1. Sever JL, Steinmier R, Schacer SA, McCracken GH and Fuccillo DA: Latex reagent for determining IgM levels in cord and newborn sera. Presented to Federation Proceedings, Atlantic City, April, 1968. (Abstract, Fed Proc 27: 490, 1968).

 2. McCracken GH, Shinefield HR, Rausen AR, Dische MR and Eichenwald HF: A longitu­dinal study of congenital cytomegalic inclusion disease. Presented to XII International Congress of Pediatrics, Mexico City, December, 1968.

 3. McCracken GH, Hardy JB, Chen TC and Sever JL: Evaluation of a radial diffusion plate method for determining immunoglobulin levels in normal and congenitally infected infants. Presented to Conference on Immunological Responses to Peri­natal Infections sponsored by National Institute of Neurological Diseases and Stroke, Bethesda, MD, May, 1969.

 4. Shinefield HR and McCracken GH: Teratogenic and other sequelae of intrauterine cytomegalovirus infection. Presented to III International Congress on Congeni­tal Malformation. Hague, The Netherlands, September, 1969.

 5. McCracken GH: Clinical pharmacology of gentamicin in newborn infants. Presented to the 10th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 20, 1970.

 6. McCracken GH: Penetration of kanamycin, gentamicin and ampicillin into spinal fluid of young infants. Presented to the 10th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 20, 1970.

 7. McCracken GH and Luby JP: Cytosine arabinoside in congenital cytomegalic inclu­sion disease. Presented at the 11th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, 1971.

 8. Kaplan JM, Snyder E and McCracken GH: Determination of antimicrobial activity in tissue. Presented to the Clinical Pharmacology and Therapeutics Meetings, Houston, TX, March 10, 1972.

 9. McCracken GH and Weinberg AG: Atypical chronic granulomatous disease of child­hood. Presented to the Society for Pediatric Research, Washington, DC, May 25, 1972.

10. McCracken GH: The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis. Presented to the Society for Pediatric Research, Washing­ton, DC, May 25, 1972.

11. Ginsburg C and McCracken GH: Clinical pharmacology of penicillin in newborn infants. Presented at the 12th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1972.

12. McCracken GH and Chrane DF: Evaluation of acute and long-term toxicity of gentamicin administered to newborn infants. Presented to the 12th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1972.

13. McCracken GH, Nelson JD and Thomas ML: Discrepancy between carbenicillin and ampicillin against enterococci and Listeria. Presented to the 12th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1972.

14. Kaplan JM and McCracken GH: Clinical pharmacology of ampicillin in neonates. Presented to the 13th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1973.

15. Kaplan JM and McCracken GH: Pharmacologic and serologic studies in infants with positive serologies. Presented to the 13th Interscience Conference on Anti­microbial Agents and Chemotherapy, September, 1973.

16. McCracken GH, Robbins JR, Gotchlich E, Orskov I, Orskov F and Ginsburg CM: Escherichia coli K1 antigen associated with neonatal meningitis. Presented to the 13th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1973.

17. McCracken GH, Sarff LD, Glode MP, Robbins JB, Schiffer M, Orskov F and Orskov I: The clinical significance of Escherichia coli K1 antigen in neonatal meningitis. Presented to the Society of Pediatric Research, Washington, DC, 1974.

18. McCracken GH: Factors affecting gastrointestinal absorption of antibiotics. Presented to the 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1974.

19. Howard JB and McCracken GH: Pharmacologic studies of methicillin and dicloxa­cillin in experimental osteomyelitis. Presented to the 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1974.

20. Howard JB and McCracken GH: Clinical pharmacology of kanamycin and BB-K8 in neonates. Presented to the 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1974.

21. Sarff LD, McCracken GH, Robbins JB, Orskov F and Orskov I: Epidemiology of E. coli K1 colonization of neonates. Presented to the 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1974.

22. McCracken GH: Evaluation of intrathecal therapy for meningitis due to Gram­-negative enteric bacteria. Presented to the American Pediatric Society, Denver, April, 1975.

23. Sarff LD and McCracken GH: Clinical pharmacology and toxicity of methicillin in infants and children. Presented to the 15th Interscience Conference on Anti­microbial Agents and Chemotherapy, September, 1975.

24. McCracken GH: Pharmacology of the cephalosporins in pediatric patients. Pre­sented to the 15th Interscience Conference on Antimicrobial Agents and Chemo­therapy, September, 1975.

25. McCracken GH, Sarff LD, Robbins JB, Glode M, Kaiser B and Hanson L: Ontogeny of serum and secretory K1 antibodies. Presented to the American Pediatric Society, St. Louis, April 29, 1976.

26. Ginsburg CM, Schneerson R, McCracken GH and Robbins JB: E. coli K100 coloniza­tion in patients with Haemophilus influenzae type b (HITB) disease. Presented to the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October, 1976.

27. Wientzen R and McCracken GH: Localization of urinary tract infection and dura­tion of antimicrobial therapy. Presented to the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October, 1976.

28. Tetzlaff T, McCracken GH and Nelson JD: Oral antibiotic therapy for osteomyeli­tis and septic arthritis of childhood. Presented to the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October, 1976.

29. McCracken GH and Ginsburg CM: Pharmacokinetics of cefaclor in infants. Pre­sent­ed to 10th International Congress of Chemotherapy, Zurich, Switzerland, Septem­ber, 1977.

30. Ginsburg CM, McCracken GH and Parke JC: Haemophilus influenzae type b disease in a day care center. Presented to the American Pediatric Society, San Francisco, April, 1977.

31. Ginsburg CM and McCracken GH: Bioavailability of oral antibiotics in infants and children. Presented to 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York City, October, 1977.

32. Siegel JD and McCracken GH: Pharmacology of netilmicin in neonates. Presented to the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October, 1978.

33. Ginsburg CM and McCracken GH: Pharmacology of amoxicillin in infants and chil­dren. Presented to the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October, 1978.

34. Wientzen RL, Nelson JD, McCracken GH, Kramer R, and Prestidge C: Double-blind controlled trial of tobramycin or placebo therapy for acute pulmonary exacerba­tions. Presented to the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October, 1978.

35. Schaad UB, McCracken GH and Nelson JD: Pharmacokinetics of vancomycin in pedi­at­ric patients. Presented to the Society for Pediatric Research, Atlanta, GA, May, 1979.

36. McCracken GH and Mize, SG: Intraventricular therapy of neonatal meningitis caused by Gram-negative enteric bacilli. Presented to the American Pediatric Society, Atlanta, GA, May, 1979.

37. Sirinavin S, McCracken GH and Nelson JD: Gentamicin therapy in children with renal failure. Presented to 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, October, 1979.

38. Schaad UB and McCracken GH: Pharmacokinetics and bacteriologic efficacy of LY 127935. Presented to 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, October, 1979.

39. Siegel JD, McCracken GH, and Rosenfeld CR: Effect of a single dose of penicillin on neonatal colonization with groups B and D streptococci. Presented to 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, October, 1979.

40. Schaad UB and McCracken GH: Serum pharmacokinetics and CSF concentrations of moxalactam (LY 127395) in neonates and young infants. Presented to the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1980.

41. Schaad UB and McCracken GH: Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone and RO 13-9904 in experimental E. coli K1 and group B streptococcal meningitis. Presented to the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1980.

42. Trincher RC, Cox F, Rissing JP, Patton M, Granoff DM and McCracken GH: Rifampin prophylaxis in Haemophilus influenzae type b meningitis. Presented to the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1980.

43. Zweighaft T and McCracken GH: In vitro effect of rifampin and trimethoprim against Haemophilus influenzae type b. Presented to the 81st Annual Meeting of the American Society of Microbiology, March, 1981.

44. Murphy T, Chrane DF, McCracken GH and Nelson JD: Rifampin chemoprophylaxis of invasive disease due to Haemophilus influenzae type b. Presented to the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago.

45. Siegel JD, McCracken GH and Rosenfeld CR: Penicillin prophylaxis of group B streptococcal infections in neonates. Presented to the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago.

46. Ginsburg CM and McCracken GH: Salivary penetration of antibiotic after oral administration. Presented to the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago.

47. McCracken GH, Nelson JD and Grimm L: Pharmacokinetics and bacteriologic efficacy of moxalactam, ceftriaxone, cefoperazone and cefuroxime in experimental S. pneumoniae and H. influenzae meningitis. Presented to the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago.

48. Del Rio MA, McCracken GH, Nelson JD and Chrane DF: Pharmacokinetics of cefur­oxime and ceftriaxone in serum and cerebrospinal fluid of patients with bacte­ri­al meningitis. Presented to the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago.

49. Preheim LC, McCracken GH, Jubelirer DP, Sanders CC and Barrett FF: Moxalactam penetration into brain abscess. Presented to the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago.

50. Finitzo-Hieber T, Brown KC and McCracken GH: ABR findings in preterm infants treated with aminoglycoside antibiotics. Presented to the American Speech and Hearing Assoc., Los Angeles, November 20, 1981.

51. Ginsburg CM and McCracken GH: Bioavailability of griseofulvin in children. Presented to the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

52. Murphy TV, McCracken GH, Gulig PA and Hansen EJ: Failure of rifampin prophylaxis to prevent Haemophilus influenzae type b disease in a day care center. Pre­sent­ed to the 22nd Interscience Conference on Antimicrobial Agents and Chemo­therapy, Miami Beach, FL, October, 1982.

53. Odio C, Mohs E, Sklar F, McCracken GH and Nelson JD: Vancomycin prophylaxis for cerebrospinal fluid shunt procedures. Presented to the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

54. Murphy TV, Chrane DF, McCracken GH, Krause EB and Granoff DM: Pharyngeal colo­ni­zation rates of Haemophilus influenzae type b, biotype 1 and group A beta­-hemolytic streptococcus in a day care center. Presented to the 22nd Inter­science Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

55. Sakata Y, Boccazzi A and McCracken GH: Pharmacokinetics and bacteriologic efficacy of ceftazidime in experimental S. pneumoniae, H. influenzae and E. coli meningitis. Presented to the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

56. McCracken GH, Siegel JD and Threlkeld N: Clinical pharmacology of ceftriaxone in newborn infants. Presented to the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

57. Del Rio MA, Chrane DF, Shelton S, McCracken GH and Nelson JD: Ceftriaxone versus standard therapy for acute bacterial meningitis in infants and children. Presented to the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

58. McCracken GH: Use of new beta-lactam antibiotics in pediatrics. Presented to the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, October, 1982.

59. Lin T-Y, Chrane DF, Nelson JD and McCracken GH Jr: 7 versus 10 days of ceftri­axone (CTR) therapy for meningitis in infants and children. Presented to 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Las Vegas, October, 1983.

60. Odio CM and McCracken GH Jr: Pharmacokinetics and bacteriologic effica­cy of mezlocillin (MEZ) in experimental E. coli (EC) and Listeria monocytogenes (LM) meningitis. Presented to 23 Interscience Conference on Antimicrobial Agents and Chemotherapy. Las Vegas, October, 1983.

61. Odio CM, Threlkeld N, Thomas M and McCracken GH Jr: Pharmacokinetics and serum bactericidal activity of mezlocillin (MEZ) in neonates. Presented to 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Las Vegas, October, 1983.

62. Sakata Y, Thomas ML, McCracken GH Jr: Treatment of experimental menin­gitis due to penicillin-insensitive (PI) or penicillin-resistant (PR) S. pneumoniae (Sp). Presented to 23rd Interscience Conference on Antimicrobial Agents and Chemo­therapy. Las Vegas, October, 1983.

63. Jackson MA, Shelton S, Nelson JD and McCracken GH Jr: The spectrum of disease due to relatively penicillin-resistant pneumococci in pediatric patients. Presented to 23rd Interscience Conference on Antimicrobial Agents and Chemo­therapy. Las Vegas, October, 1983.

64. Ginsburg CM and McCracken GH Jr: Intolerance to twice daily doses of erythro­mycin ethylsuccinate (EES) for therapy of streptococcal (GAS) pharyngitis in children. Presented to 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Las Vegas, October, 1983.

65. Sakata Y, Boccazzi A, Olsen KD and McCracken GH Jr: Pharmacokinetics and bacte­riologic efficacy of aztreonam (AZ) in experimental H. influenzae and E. coli meningitis. Presented to 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Las Vegas, October, 1983.

66. Kimura A, McCracken GH, Gulig PA, Loftus TA and Hansen EJ: Identifica­tion of an immunogenic, high molecular weight outer membrane protein of Haemophilus influenzae type b as a protective antigen. Presented at American Society for Microbiology, Annual Meeting, March, 1984.

67. Freij BJ, McCracken GH, Olsen KD and Threlkeld N: Pharmacokinetics of imipenem and cilastatin in newborns. Presented to 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October, 1984.

68. Odio CM, Faingezicht I, Mohs E, Salas JL and McCracken GH: Cefotaxime versus conventional therapy for bacterial meningitis in infants and children. Pre­sent­ed to 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October, 1984.

69. Siegel JD, McCracken GH and Rosenfeld CR: Effect of single dose peni­cillin administered to all neonates on rates of systemic infections. Presented to 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October, 1984.

70. Ginsburg CM, McCracken GH and Weintrub L: Pharmacokinetics and serum bacteri­cidal activity of cefuroxime axetil. Presented to 24th Inter­science Conference on Antimicrobial Agents and Chemotherapy, Washing­ton, DC, October, 1984.

71. Madrigal G, Odio CM, Mohs E, Guevara J and McCracken GH: Short-term antibiotic therapy for urinary tract infections in infants and chil­dren. Presented to 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October, 1984.

72. Ginsburg CM, McCracken GH, Crow SD et al: Seroepidemiology of the Group A streptococcal carriage state in a private pediatric practice. Presented To 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October, 1984.

73. Ginsburg CM, and McCracken GH, Jr: Reculture of children with group A strepto­coccal (GAS) tonsillopharyngitis (TP). Presented at 25th Interscience Confer­ence on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

74. Israele V, McCracken GH, Jr and Darabi A: Characteristics of Escherichia coli strains from young male infants with urinary tract infections (UTI). Presented at 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

75. Odio CM, Umana MA, Salas JL, Saenz A, Mohs E and McCracken GH Jr: Comparative evaluation of ceftazidime (CZ) versus amikacin/carbenicillin (A/C) in neonates with bacterial infections. Presented at 25th Interscience Conference on Anti­microbial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

76. Likitnukul S, McCracken GH Jr, Nelson JD: Arthritis in children with bacterial meningitis. Presented at 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

77. Freij BJ, Syrogiannopoulos G, McCracken GH Jr, Chrane D and Olsen KD: Cerebro­spinal fluid (CSF) hypoxanthine (HPX) and lactate (LACT) profiles in bacterial meningitis (BM). Presented at 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

78. Israele V, McCracken GH Jr, Threlkeld N and Darabi A: Pharmacokinetics of vancomycin (V) in young infants. Presented at 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

79. Syrogiannopoulos G, McCracken GH Jr, and Olsen K: Effect of mannitol (M) treat­ment on CSF pressure (CSFP), lactate (L), hypoxanthine (HPX), bacteria count and brain water content (BW) in experimental Haemophilus influenzae (Hib) meningi­tis. Presented at 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

80. Syrogiannopoulos G, McCracken GH Jr, and Olsen K: The effect of dexamethasone (DX) treatment (Rx) on CSF pressure (CP) and brain water content (BW) in exper­i­mental Haemophilus influenzae type b (Hib) meningitis. Presented at 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 30-October 2, 1985.

81. Odio C, Umana M, Salas J, McCracken GH: Treatment of CSF-shunt infections. Presented to the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

82. Lebel MH, McCracken GH, Ginsburg CM and Shelton S: Comparative in vitro activity of BMY-28100 and cefaclor against pathogens of otitis media and pharyngitis. Presented to the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

83. Likitnukul S, McCracken GH, Threlkeld N, Darabi A, and Olsen K: Pharmacokinetics and plasma bactericidal activity of aztreonam in low birthweight infants. Presented to the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

84. Likitnukul S, Kusmiesz H, Nelson JD and McCracken GH: An investigation into the role of genital mycoplasmas in young infants with suspected sepsis. Presented to the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

85. Israele V and McCracken GH: Role of Tamm Horsfall protein in the pathogenesis of urinary tract infections in pediatric patients. Presented to the 26th Inter­science Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

86. Syrogiannopoulos GA, Hansen EJ, Erwin AL, Munford RS and McCracken GH: The role of Haemophilus influenzae type b lipopolysaccharide in the induction of menin­geal inflammation. Presented to the 26th Interscience Conference on Antimicro­bial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

87. Syrogiannopoulos GA, Freij BJ, Chrane DF, Olsen KD and McCracken GH: Dexametha­sone treatment for bacterial meningitis in infants and children. Presented to the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 29-October 1, 1986.

88. Umana MA, Odio M, Salas JL and McCracken GH: Comparative evaluation of Aztreonam/Ampicillin versus Amikacin/Ampicillin in Neonates with bacterial infections. Presented to the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 4-7, 1987.

89. Syrogiannopoulos GA, McCracken GH and Hansen EJ: Induction of meningeal in­flammation by outer membrane vesicles of Haemophilus influenzae type b. Pre­sented to the 27th Interscience Conference on Antimicrobial Agents and Chemo­therapy, New York, October 4-7, 1987.

90. Syrogiannopoulos GA, Al-Sabbagh A, Olsen KD and McCracken GH: Evaluation of Ticarcillin/Clavulanic Acid in Experimental Escherichia coli K1 and Haemophilus influenzae type b (Hib) meningitis. Presented to the 27th Interscience Confer­ence on Antimicrobial Agents and Chemotherapy, New York, October 4-7, 1987.

91. Lebel MH, Chrane DF and McCracken GH: Dexamethasone and Ceftriaxone therapy of bacterial meningitis in infants and children. Presented to the 27th Inter­science Conference on Antimicrobial Agents and Chemotherapy, New York, October 4-7, 1987.

92. Lebel MH, Kusmiesz H and McCracken GH: Repeat spinal fluid culture to predict outcome of bacterial meningitis in infants and children. Presented to the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 4-7, 1987.

93. Sanchez PJ, McCracken GH, Wendel GD and Norgard MV: Specificity of the fetal IgM response to Treponema pallidum antigens during congenital syphilis. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 4-7, 1987.

94. Ginsburg CM, McCracken GH: Domestic dogs and cats are not reservoirs for group A streptococcus. Presented to Society for Pediatric Research, Washington, DC, May, 1988.

95. Lebel MH, Hoyt MJ, Stewart SM, Kennard BD, McCracken GH: One year follow-up of dexamethasone and ceftriaxone therapy of bacterial meningitis. Presented to American Pediatric Society, Washington, DC, May, 1988.

96. Sanchez P, Cushion, N Threlkeld N, Dorne P, Siegel JD, McCracken GH: What is the significance of a positive urine group B streptococcal latex agglutination test in neonates? Presented to Society for Pediatric Research, Washington, DC, May, 1988.

97. Lebel MH, Hoyt MJ, Rollins NK and McCracken GH: Evaluation of magnetic resonance imaging (MRI) in infants and children with bacterial meningitis. Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

98. Lebel MH, Hoyt, MJ, and McCracken GH: Comparison of cefuroxime (CSX) and ceftri­axone (CTX) for therapy of meningitis in 333 infants and children. Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

99. Mustafa M, Ramilo O, Beutler B, Hansen EJ and McCracken GH: Modulation of inflammation and cachectin (TNFα) activity in relation to treatment (Rx) of experimental Haemophilus influenzae type b (Hib) meningitis. Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

100. Sanchez PJ, McCracken GH, Wendel G, Olsen KD, Threlkeld N and Norgard MV: IgM antibody to Treponema pallidum (Tp) in CSF of infants with congenital syphilis. Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

101. Waagner DC, Mustafa MM, Faucher DJ and McCracken GH: The effect of diphenyl­hydantoin (DPH) on inappropriate secretion of arginine vasopressin (IAVP) in experimental lapine meningitis. Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

102. Lebel MH, Ramilo O, Olsen KD, Beutler B and McCracken GH: Measurement of inter­leukin-1β (IL-1β) and cachectin (TNFα) in CSF of patients with bacterial menin­gitis (BM). Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

103. Mustafa MM, Ramilo O, Beutler B, Hansen EJ and McCracken GH: Measurement of CSF cachectin (TNFα) activity in experimental Haemophilus influenzae type b (Hib) meningitis. Presented to the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.

104. Mustafa MM, Ramilo O, Mertsola J, Sáez-Llorens X, Olsen KD and McCracken GH Jr: Concentrations of IL-1β and TNF in CSF and outcome from neonatal gram-negative enteric bacillary meningitis. Presented to American Pediatric Society, Washington, DC, May, 1989.

105. Sanchez PJ, Wendel GD, McCracken GH Jr and Norgard MV: Fetal IgM response to Treponema pallidum antigens in asymptomatic infants with suspected congenital syphilis. Presented to American Pediatric Society, Washington, DC, May, 1989.

106. Ramilo O, Mustafa MM, Porter J, Olsen KD, Luby J and McCracken, GH, Jr.: Concentration of IL-Iβ and TNF in CSF of infants and children with meningitis. Presented to American Pediatric Society, Washington, DC, May, 1989.

107. Waagner DC, Hoyt MJ, Finitzo T and McCracken, GH Jr: Administration of dexamethasone (DXM) before antibiotic (ABX) therapy for bacterial meningitis. Presented to the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989.

108. Ramilo O, Mertsola J, Mustafa MM, Sáez-Llorens X, Olsen KD, Ohkawara S, Beutler B, Hansen EJ, Yoshinaga M and McCracken GH Jr: Interleukin-1β (IL-1β) appears to mediate CSF inflammation in rabbits. Presented to the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989.

109. Mustafa MM, Ramilo O, Sáez-Llorens X, Magness R and McCracken GH Jr: Prostaglandin E2 and I2 (PGE2, PGI2) concentrations in CSF of infants and children with bacterial meningitis. Presented to the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989.

110. Mertsola J, Ramilo O, Sáez-Llorens X, Mustafa M, McCracken GH Jr, and Hansen EJ: Specific detection of Haemophilus influenzae type b lipooligosaccharide (Hib-LOS) by immunoassays. Presented to the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989.

111. Sáez-Llorens X, Ramilo O, Mustafa MM, Mertsola J, De Alba C, Olsen KD, Hansen EJ and McCracken GH Jr: Pentoxifylline (PTX) modulates meningeal inflammation induced by Haemophilus influenzae (Hib) or by its lipooligosaccharide (LOS) in rabbits. Presented to the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, September, 1989.

112. Sanchez PJ, Wendel GD, McCracken GH Jr, Norgard MV: Congenital syphilis (CS) and HIV infection. Presented to APS/SPR, Anaheim, CA, May, 1990.

113. Ramilo O, Sáez-Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, McCracken GH Jr: Tumor necrosis factor (TNFα) and interleukin-1β (IL-1β) are initiators of meningeal inflammation. Presented to APS/SPR, Anaheim, CA, May, 1990.

114. Waagner DC, Kennedy WA, Hoyt MJ, Finitzo T and McCracken GH Jr: Timing of dexamethasone (DXM) therapy (RX) for bacterial meningitis (BM). Presented to APS/SPR, Anaheim, CA, May, 1990.

115. Odio CM, Faingezicht I, Paris M, Sáez-Llorens X, McCracken GH Jr: Double-blinded, randomized, placebo-controlled trial of dexamethasone (DXM) therapy (Rx) for bacterial meningitis (BM). Presented to APS/SPR, Anaheim, CA, May, 1990.

116. Velasco S, Tarlow M, McCracken G and Nisen P: Modulation of interleukin-1 gene expression in astrocytomas in vitro. Presented to APS/SPR, Anaheim, CA, May, 1990.

117. Sáez-Llorens X, Jafari HS, Hansen EJ, McCracken GH Jr: Haemophilus influenzae type b (Hib) lipooligosaccharide (LOS) induces suppurative arthritis in rabbits. Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

118. Mertsola J, Cope LD, Sáez-Llorens X, Ramilo O, Kennedy W, McCracken GH Jr and Hansen EJ: Expression of Haemophilus influenzae type b (Hib) lipooligosaccharide (LOS) epitopes in vivo and in vitro. Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

119. Jafari HS, Sáez-Llorens X, Grimprel E and McCracken GH Jr: TNFα and meningeal inflammation in experimental Candida albicans meningitis. Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

120. Odio CM, Paris MM, Alfaro B and McCracken GH Jr: Prophylactic intravenous immune globulin (PIVIG) for prevention of sepsis (PS) in low birth weight neonates (LBWN). Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

121. Kennedy WA, Mertsola J, Waagner D, Sáez-Llorens X, Hansen EJ and McCracken GH Jr: CSF endotoxin (LOS) concentration correlates with clinical severity and neurological outcome of Haemophilus influenzae (Hib) meningitis. Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

122. Unhanand M, Mustafa MM, McCracken GH Jr and Nelson JD: Gram-negative enteric bacillary meningitis (GNEBM) in pediatric patients: Twenty years experience. Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

123. Mertsola J, Cope LD, Munford RS, McCracken GH Jr and Hansen EJ: A new method for specific detection of bacteremia and endotoxemia. Presented to the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-14, 1990.

124. Sanchez PJ, Wendel GD, Grimprel E, Goldberg MS, McCracken GH Jr, Radolf JD, Norgard MV: Diagnosis of congenital neurosyphilis by the rabbit infectivity test (RIT) and polymerase chain reaction (PCR). Presented to APS/SPR, New Orleans, LA, May, 1991.

125. Sáez-Llorens X, Jafari H, Severien C, Parras F, Olsen K, Hansen E and McCracken GH Jr: Enhanced modulation of meningeal inflammation and brain edema by IV administration of anti-CD18 MAB (1B4) and dexamethasone (DXM) to rabbits with H. influenzae type b (Hib) meningitis. Presented to APS/SPR, New Orleans, LA, May, 1991.

126. Kennedy WA, Olsen KD, McCracken GH Jr: Cytokines as indicators of bacterial or fungal infections of CSF shunts and peritoneal fluid. Presented to the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 30-October 2, 1991.

127. Kennedy WA, Hoyt MJ, McCracken GH Jr: the role of dexamethasone therapy in children with pneumococcal meningitis. Presented to the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 30-October 2, 1991.

128. Jafari H, Sáez-Llorens X, Severien C, Parras F, Olsen K and McCracken GH Jr: Modulation of inflammation by dexamethasone and Anti-CD18 antibodies (1B4) in experimental suppurative arthritis. Presented to the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 30-October 2, 1991.

129. Friedland IR, Jafari H, Rinderknecht S, Ehrett S, Saxen H, Olsen K and McCracken, GH Jr: The effect of antibiotic type and dosage on the inflammatory process in experimental meningitis. Presented to the SPR/APS meetings, Baltimore, MD, 1992.

130. Jafari H, Sáez-Llorens X, Severien C, Parras F, Abramowsky C, Olsen K and McCracken GH Jr: Effects of antifungal therapy on inflammation, sterilization and histology in experimental C. albicans meningitis. Presented to the SPR/APS meetings, Baltimore, MD, 1992.

131. Jafari H, Friedland I, Ehrett S, Rinderknecht S, Paris M, Burns D, Thonar E, and McCracken GH Jr: Effects of dexamethasone and anti-CD18 antibodies on H. influenzae type B (HIB). Presented to the SPR/APS meetings, Baltimore, MD, 1992.

132. Jafari H, Sáez-Llorens X, Rinderknecht S, Friedland I, Ehrett S, Thonar E and McCracken GH Jr: Regulation of stromelysin as a mediator of cartilage destruction by cytokines in experimental arthritis. Presented to the Annual Meeting, Infectious Diseases Society of America, October 10, Anaheim, CA, October 10-12, 1992.

133. Friedland I, Ehrett S, Jafari H, Rinderknecht S, Saxen H, Coulthard M and McCracken, GH Jr: Comparison of efficacy and endotoxin (LPS) release by meropenem (MRP) vs. cefotaxime (CTX) in experimental E. coli meningitis. Presented to the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11-14, 1992.

134. Odio C, Salas J, Hererra M, McCracken GH Jr: Treatment of CSF shunt infections. Presented to the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11-14, 1992.

135. Friedland IR, Paris M, Shelton S, McCracken GH Jr: In vitro studies of antibiotic combinations against penicillin-resistant and susceptible Streptococcus pneumoniae. Presented to Annual Meeting of the American Microbiology Society, May, 1993.

136. Paris M, Friedland IR, Ehrett S, Hickey S, Olsen K, Thonar E, McCracken GH Jr: Effect of interleukin-1 receptor antagonist (IL-1 RA) and soluble tumor necrosis factor-receptor (s TNF-R) in animal model of infection. Presented to 1993 Infectious Diseases Society of America meeting, New Orleans, LA, October, 1993.

137. Friedland IR, Paris M, Shelton S, McCracken GH Jr: Comparison of time-kill studies and the decimal activity assay for detection of antibiotic synergy against penicillin-resistant S. pneumoniae. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, October, 1993.

138. Friedland IR, Paris M, Ehrett S, Hickey S, McCracken GH Jr: Cefpirome therapy in experimental cephalosporin‑resistant S. pneumoniae meningitis. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, 1993.

139. Paris MM, Trujillo M, Hickey SM, McCracken GH: Comparison of CP-99,219, a new fluoroquinolone vs vancomycin with or without rifampin in the treatment of experimental arthritis caused by methicillin resistant *Staphylococcus aureus*. Presented to the Infectious Diseases Society of America meeting. Orlando, FL, October 1994.

140. Odio CM, Zaglul C, Faingezicht I, Ramirez L, Guevara J, Nassar M, Campos Z, Paris M, Olsen K and McCracken GH: A double-blind controlled study of 1 vs 4 days of dexamethasone for patients with purulent meningitis. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 1994.

141. Paris MM, Hickey SM, Trujillo M, Shelton S and McCracken GH: Efficacy of CP-99,219, a new fluoroquinolone for therapy of experimental meningitis caused by penicillin and cephalosporin-resistant *Staphylococcus pneumoniae*. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 1994.

142. Kimberlin DW, McCracken GH, Nisen PD: Mechanism of dexamethasone action in bacterial meningitis: Dexamethasone destabilizes interleukin-1β mRNA in the human astrocytoma cell line U-373MG. Presented to the Infectious Disease Society of America meeting. Orlando, FL, October 1994.

143. Sáez-Llorens X, Ah Chu M, Cortés L, Castao E, Torres A, Suárez M, Bissot A, Reyes W and McCracken GH: Ceftriaxone intrapartum prophylaxis. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 1994.

144. Hickey S, Ehrett S, Krisher K, Olsen K and McCracken GH: Polymerase chain reaction for the diagnosis of enteroviral meningitis. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 1994.

145. Paris MM, Hickey SM, Uscher MI, Shelton S, Olsen K and McCracken GH: Dexamethasone therapy and CSF sterilization in experimental meningitis produced by penicillin and cephalosporin-resistant *Streptococcus pneumoniae*. Presented to the American Pediatric Society and The Society for Pediatric Research. Seattle, WA, May 1994.

146. Paris MM, Shelton S, Krisher K and McCracken GH: Otitis media caused by penicillin and cephalosporin resistant *Streptococcus pneumoniae*. Presented to the American Pediatric Society and The Society for Pediatric Research. Seattle, WA, May 1994.

147. Paris MM, Shelton S, Trujillo M, Hickey S and McCracken GH: Clindamycin therapy for experimental meningitis caused by penicillin and cephalosporin resistant *Streptococcus pneumoniae*. Presented to the American Pediatric Society and The Society for Pediatric Research, San Diego, CA, May 1995.

148. Ahmed AA, Ehrett S, Hickey S, Trujillo M, Brito F, Goto C, Olsen K, Krisher K and McCracken GH: Cerebrospinal fluid (CSF) indices in the newborn. Presented to the Infectious Diseases Society of America meeting. San Franciso, CA, September 1995.

149. Trujillo T, Ehrett S, Hoyt-Sehnert MJ, Shelton S and McCracken GH: Safety and efficacy of Cefprozil as part of a parenteral-oral antibiotic regimen in the treatment of suppurative skeletal infections in children. Presented at the Infectious Diseases Society of America meeting. San Francisco, CA, September 1995.

150. Ahmed A, Paris M, Trujillo M, Hickey S, Shelton S and McCracken GH: Once-daily aminoglycoside dosing in the rabbit meningitis model. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995.

151. Paris M, Hickey S, Trujillo M, Ahmed A, Olsen K and McCracken GH: Effect of interleukin-10 (IL-10) in experimental bacterial meningitis. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995.

152. Ahmed A, Hickey SM, Trujillo M, Goto C, Brito FI, Olsen KD, Krisher KK and McCracken GH: Clinical utility of polymerase chain reaction (PRC) in diagnosis of enteroviral meningitis. Presented to the The American Pediatric Society and The Society for Pediatric Research, May 1996.

153. Aebi C, Stone B, Beucer M, Cope LD, Maciver I, Thomas SE, McCracken GH, Sparling PF and Hansen EJ: Expression of the CopB outer membrane protein by *Moraxella catarrhalis* is regulated by iron and affects iron acquisition from transferrin and lactoferrin. Presented to The American Pediatric Society and The Society for Pediatric Research, May 1996.

154. Rotbart H, McCracken G, Dagan R, Pichichero M, McLinn S, Whitley R, Modlin J, McCarty J, Cascino M, O'Connell J, Menegus M, Reidenberg and B, Blum D: PCR of multiple specimen types in the diagnosis of outpatient enterovirus infections. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, September 1996.

155. Aebi C, Cope LD, Latimer JL, Thomas SE, Slaughter CA, McCracken GH and Hansen EJ: *Moraxella catarrhalis* outer membrane protein CopB: Identification of a peptide that contains a protective epitope. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, September 1996.

156. Ahmed A, Trujillo M, Wubbel L, Lutsar I, Shelton S, Olsen K and McCracken GH: Pharmacodynamics of vancomycin in experimental cephalosporin-resistant pneumococcal meningitis. Presented at the Infectious Diseases Society of America meeting, September 1996.

157. Wubbel L, Jafri H, Olsen K, Shelton S, Rogers B, Gambill G, Patel P, Keyser E, Cassell G and McCracken GH: *Mycoplasma pneumoniae*: A mouse pneumonia model. Presented at the Infectious Diseases Society of America meeting, San Francisco, CA, September 1997.

158. Wubbel L, Ahmed A, Trujillo M, McCoig C, Jafri H, Olsen K, Shelton S, Muniz L, Brito F, Hoyt J, Bakken D, Carubelli C, Abram T and McCracken GH: Evaluation of azithromycin in the treatment of pneumonia in ambulatory children: A randomized trial employing amoxicillin clavulanate or erythromycin estolate as comparative standard therapy.

159. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Presented at the Infectious Diseases Society of America meeting, San Francisco, CA, September 1997.

160. Lutsar I, Friedland IR, Wubbel L, Ahmed A, Trujillo M, Jafri H, McCoig CC, and McCracken GH: Timing of dexamethasone therapy in experimental pneumococcal meningitis. Presented at the Infectious Diseases Society of America meeting, San Francisco, CA, September 1997.

161. McCoig C, Wubbel L, Lutsar I, Friedland IR, Bastero R, Jafri H, Shelton S, Olsen K and McCracken, GH: Pharmacodynamics and bactericidal activity of trovafloxacin in CSF in experimental cephalosporin-resistant pneumococcal meningitis. Presented at the Infectious Diseases Society of America meeting, San Francisco, CA, September 1997.

162. Burch D, McCracken GH and Moonsammy G: Clinical profile of a new formulation of amoxicillin/clavulanate for the treatment of acute otitis media. Presented at the Infectious Diseases Society of America meeting, San Francisco, CA, September 1997.

163. Aebi C, Cope LD, Latimer JL, Lumbley SL, McCracken GH, Hansen EJ: A *uspA1* mutant of *Moraxella catarrhalis* demonstrates reduced ability to adhere to human epithelial cells in vitro. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 1997.

1. Jafri H, Wubbel L, McCracken GH, Ramilo O: Characterization of inflammatory response elicited by *Mycoplasma pneumoniae* in an experimental mouse pneumonia model. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
2. Ghaffar F, Katz K, McCracken GH, Friedland IR: Antibiotic therapy is associated with increased carriage of resistant viridans streptococci but not resistant *S. pneumoniae*. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
3. Ng W, Lutsar I, Wubbel L, Ghaffar F, Jafri H, McCracken GH, Friedland IR: Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant *Streptococcus pneumonaie* pneumonia. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
4. Lutsar I, Friedland IR, Jafri H, Wubbel L, Ng W, Ghaffar F, McCoig CC, McCracken GH: Pharmacodynamics of gatifloxacin in CSF in experimental *E. coli* and pneumococcal meningitis. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
5. Ghaffar G, McCracken GH, Friedland IR: Effect of amoxcillin/clavulanate 7:1 vs azithromycin on nasopharyngeal carriage and resistance of *S. pneumoniae* and *H. influenzae* in children with acute otitis media. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
6. Lutsar I, Friedland IR, Jafri H, Wubbel L, Ng W, Ghaffar F, McCracken GH: Limited efficacy of recombinant bactericidal/permeability-increasing protein in experimental meningitis. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
7. Rodriguez-Cerrato V, Michelow IC, Ghaffar F, Jafri HS, Hardy RD, McCoig CC, Olsen K, McCracken GH: Pharmacodynamics and bactericidal activity of moxifloxacin in experimental *Escherichia coli* meningitis. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999.
8. Hardy RD, Jafri H, Wordemann M, Rogers BB, Duffy L, Cassell G, Ramilo O, McCracken G: *Mycoplasma pneumoniae*: Chronic infection in the mouse pneumonia model. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999.
9. Ghaffar F, Katz K, Muniz LS, Reynolds L, Smith JS, Davis P, Friedland IR, McCracken GH: Characterization of nasopharyngeal isolates of *Streptococcus pneumoniae* in children treated for acute otitis media. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999.
10. Hardy RD, Jafri HS, Wördemann, McCracken GH, Ramilo O: Pulmonary cytokines and chemokines in acute murine Mycoplasma pneumoniae (MP) pneumonia. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000.
11. Hardy RD, Jafri HS, Hatfield J, Wördemann M, Baldwin H, Rogers BB, McCracken GH, Ramilo O: Effect of clarithromycin on acute murine Mycoplasma pneumoniae pneumonia. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000.
12. Sáez-Llorens X, Feris JM, Klugman KP, Hussey GD, Frenck Jr., RW, Arguedas-Mohs A, Carvalho LH, Vargas S, McCoig CC, Bradley J, Arrieta A, Wald E, Pancorbo S, McCracken Jr., GH: Use of a quinolone in children with bacterial meningitis (BM). A comparative study of trovafloxacin and ceftriaxone  vancomycin. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000.
13. Rodriguez-Cerrato V, Ghaffar F, Saavedra J, Michelow IC, Hardy RD, Iglehart J, Olsen K, McCracken GH: Evaluation of BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000.
14. Rodriguez-Cerrato V, McCoig CC, Saaveda J, Barton T, Michelow IC, Hardy RC, Bowlware K, Iglehart J, Olsen K, McCracken GH: Evaluation of new quinolones in experimental vancomycin-tolerant pneumococcal meningitis. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 2001.
15. Hardy RD, Jafri HS, Olsen K, Iglehart J, Hatfield J, Rogers BB, Patel P, Duffy L, Cassell G. Ramilo O, McCracken GH: Airway hyperreactivity and pulmonary inflammation in murine model of chronic *Mycoplasma pneumoniae*. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 2001.
16. Barton T, Ghaffar F, Muniz LS, Lozano J, McCracken GH: Effect of the 7-valent pneumococcal conjugate vaccine (PCV-7) on nasopharyngeal colonization (NP) by *Streptococcus pneumoniae* (SP) in the first six months of life. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 2001.
17. Avila-Aguero M, Blumer J, Bradley J, Saez-Llorens X, O’Ryan M, Grasela D, Lacreta F, Swingle M, McCracken GH, Jafri H: Single dose safety and pharmacokinetics (PK) of intravenous (IV) gatifloxacin in pediatric patients. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 2001.
18. Michelow IC, Hardy RD, Olsen K, Iglehart J, Rogers BB, Jafri H, McCracken GH, Ramilo O: Effectiveness of ABT-773 in an experimental model of multidrug-resistant (MDR) *Streptococcus* *pneumoniae* (Sp) bacteremic pneumonia. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 2001.
19. Rios AM, Hardy RD, Mejias A, Chavez-Bueno S, Kapur P, Rogers B, Jafri HS, McCracken GH, Ramilo O. ABT-773 for the Treatment of Experimental *Mycoplasma pneumoniae* Pneumonia. Abstract B-697. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.
20. Rios, AM, Chavez-Bueno S, Jafri, HS, Hatfield J, Rogers BB, McCracken GH, Ramilo O. Microbiologic and Immunologic Activity of Clarithromycin in a Murine Model of *Mycoplasma pneumoniae* Pneumonia. Abstract B-701. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.
21. Barton T, Ghaffar, F, McCracken GH. The Impact of Pneumococcal Conjugate Vaccine (PCV7) on Serotype Distribution in Invasive Pneumococcal Diseases (IPD) in Infants and Children. Abstract G-140. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.
22. Ghaffar F, Barton T, Muniz LS, Lozano J, McCracken GH. Effect of the 7-Valent Pneumococcal Conjugate Vaccine (PCV-7) on Nasopharyngeal Colonization (NP) by *Streptococcus pneumoniae* (Sp) in Early Life. Abstract G-834. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.
23. Hardy RD, Olsen K, Rogers BB, Ramilo O, McCracken GH. Long-term Outcome of Airway Hyperactivity in Treated Versus Untreated Acute *Mycoplasma pneumoniae* Pneumonia in a Murine Model. 103rd ASM General Meeting, Washington D.C., 2003.
24. Rios, AM, Fonseca-Aten M, Mejias A, Chavez-Bueno S, Rogers BB, Hatfield J, Jafri HS, Ramilo O, McCracken GH, Hardy RD. Impact of Therapy with the Ketolide ABT-773 on the Pulmonary Immune Response Induced by *Mycoplasma pneumoniae* in a Murine Pneumonia Model. 103rd ASM General Meeting, Washington, D.C., 2003.
25. Fonseca-Aten M, Rios AM, Mejias A, Chavez-Bueno S, Katz K, Gomez AM, McCracken GM, Hardy RD. Comparison of Disease Sevrity and Pulmonary Immune Response in *Mycoplasma pneumoniae* Pneumonia in BALB/c and C57Bl/6 Mice. Abstract B-1671. Presented at the 43nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003.
26. Rios, AM, Fonseca-Aten M, Mejias A, Chavez-Bueno S, Gomez AM, Ramilo O, McCracken GH, Hardy RD. Single High Does versus Daily-Dose Azithromycin for the Treatment of Experimental *Mycoplasma pneumoniae* Pneumonia. Abstract B-1672. Presented at the 43nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003.
27. Chavez-Bueno S, Bowlware K, Chung W, Cushion N, Cavuoti D, McCracken GH. Inducible Resistance to Clindamycin Evidenced by D-Test in Community-Acquired Methicillin Resistant *Staphylococcus aureus* (CAMRSA) in Children from 1999 to 2002: the Dallas Experience. Abstract D-246. Presented at the 43nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003.
28. Hardy, RD, Michelow IC, Rios AM, Olsen K, Lozano J, Duffy LB, McCracken GH. Comparison of Nasopharyngeal and Oropharyngeal PCR for the Diagnosis of *Mycoplasma pneumoniae* Pneumonia in Children. Abstract D-1859. Presented at the 43nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003.
29. Ghaffar F, Barton T, Lozano J, Muniz L, McCracken GH. Effect of the Booster Dose (BD) of 7-Valent Pneumoncoccal Conjugate Vaccine (PCV7) on Nasopharyngeal (NP) Carriage of Vaccine-Type (VT) *Streptococcus pneumoniae* (Sp). Abstract G-894. Presented at the 43nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003.
30. Barton T, Ghaffar F, McCracken GH. Impact of Pneumococcal Conjugate Vaccine (PCV7) on Serotype Distribution in Invasice Pneumoncoccal Diseases (IPD) in Infants and Children. Abstract 907. Presented at the 41st Infectious Diseases Society of America Conference, San Diego, California, October 9-12, 2003.
31. Messina A, Barton T, McCracken GH, Ahmad N, Ghaffar, F. Impact of Pneumococcal Conjugate Vaccine (PCV7) on Serotype Distribution in Invasive Pneumococcal Diseases (ST)

Distribution and Antibiotic Resistance in Invasive Pneumococcal Disease (IPD) in Children, Dallas, Texas from 1999-2003. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30 – November 2, 2004.

195. Rios A, Duffy L, Chavez-Bueno S, Mejias A, Jafri H, McCracken GH, Ramilo O, Hardy R. Failure of Antimicrobial Therapy to Erradícate *Mycoplasma* pneumoniae in Experimental Pneumonia is Not Due to the Development of Resistance. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30-November 2, 2004.

196. Chavez-Bueno S, Rios A, Mejias A, Fonseca-Aten M, Gomez A, Soni P, Katz K, Olsen K, Hardy R, McCracken G, Ramilo O, Jafri H. Respiratory Syncytial Virus (RSV)-Induced Pulmonary Disease is Worsened by Atypical Bacterial Infection. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30- November 2, 2004.

1. Fonseca-Aten M, Rios A, Mejias A, Chavez-Bueno S, Gomez A, McCracken GH, Hardy R. Evaluation of NVP-PDF713 for the Treatment of Experimental *Mycoplasma* pneumoniae Pneumonia. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30- November 2, 2004.
2. Bozdogan B, Chavez-Bueno S, McCracken GH, Applebaum P. Katz K. Trends In Resistance Mechanisms and Molecular Epidemiology of Pediatric Community-Acquired Methicillin Resistant S. aureus (CAMRSA) Isolates in Dallas. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30- November 2, 2004.
3. Ghaffar F, Arnaoutakis, Zhang Q, Barton T, McCracken GH, Ahmad N, Finn A. Salivary Anti-Capsular Antibodies in Infants Receiving Seven-Valent Pnuemoccocal Conjugate Vaccine (PCV7): Relationship to Nasopharyngeal (NP) Colonization. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30-November 2, 2004.
4. Messina A, Bowlware K, Lozano J, McCracken GH, Ghaffar F. Effect of Gatifloxacin (GAT) on Nasopharyngeal (NP) Carriage and Resistance of S. pneumoniae (Sp) and H. Influenzae (Hflu) in Young Children. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30 – November 2, 2004.
5. Fonseca-Aten M, Salvatore C, Mejias A, Rios A, Katz K, Gomez A, McCracken GH, Hardy R.

The Effect of LBM415 on Pulmonary Chemokine Concentrations in Experimental *Mycoplasma* pneuemoniae Pneumonia. Presented at the 45th Annual Interscience Conference on Anitmicrobial Agents and Chemotherapy, Washington DC, December 16-19, 2005.

1. Messina A, Barton T, McCracken GH, Ahmad N, Ghaffar F. Impact of Pneumococcal Conjugate Vaccine (PCV7) on Sertoype (ST) Distribution and Antibiotic Resistance in Invasive Pneumococcal Disease (IPD) in Children Dallas, Texas from 1999-2003. Presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washingon DC, December 16-19, 2005.
2. Salvatore C, Fonseca-Aten M, Gaynor K, Gomez A, McCracken GH, Hardy, R. Intranasal IL-12 Therapy Decreases *Mycoplasma* pneumoniae Clearance and Sustains Airway Hyperreactivity in Murine Pneumonia. Presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16-19, 2005